We	O	O
also	O	O
demonstrated	O	O
that	O	O
the	O	O
substituents	O	O
on	O	O
the	O	O
quinazoline	O	O
ring	O	O
possess	O	O
major	O	O
consequences	O	O
for	O	O
metabolic	O	O
polymorphism	O	O
.	O	O
In	O	O
order	O	O
to	O	O
obtain	O	O
agents	O	O
with	O	O
therapeutic	O	O
indices	O	O
superior	O	O
to	O	O
those	O	O
of	O	O
AZT	O	O
,	O	O
FLT	O	O
,	O	O
or	O	O
D4T	O	O
,	O	O
several	O	O
analogues	O	O
of	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
nucleosides	O	O
were	O	O
synthesized	O	O
.	O	O
The	O	O
alkylating	O	O
agent	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
10	O	O
or	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
11	O	O
was	O	O
prepared	O	O
by	O	O
reacting	O	O
CH	O	O
(	O	O
3	O	O
)	O	O
MgBr	O	O
with	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
CO	O	O
(	O	O
2	O	O
)	O	O
,	O	O
followed	O	O
by	O	O
reduction	O	O
with	O	O
LiAlH	O	O
(	O	O
4	O	O
)	O	O
and	O	O
iodination	O	O
with	O	O
HI	O	O
.	O	O
No	O	O
ATP	O	O
-	O	O
site	O	O
-	O	O
directed	O	O
inactivations	O	O
resulted	O	O
when	O	O
the	O	O
M	O	O
,	O	O
L	O	O
,	O	O
or	O	O
K	O	O
isozymes	O	O
of	O	O
PK	O	O
were	O	O
exposed	O	O
for	O	O
8	O	O
h	O	O
,	O	O
22	O	O
degrees	O	O
C	O	O
,	O	O
to	O	O
5	O	O
mM	O	O
levels	O	O
of	O	O
18	O	O
ATP	O	O
derivatives	O	O
or	O	O
6	O	O
analogous	O	O
ADP	O	O
derivatives	O	O
or	O	O
when	O	O
yeast	O	O
HK	O	O
or	O	O
rat	O	O
KH	O	O
I	O	O
,	O	O
II	O	O
,	O	O
or	O	O
III	O	O
was	O	O
exposed	O	O
for	O	O
6	O	O
h	O	O
,	O	O
22	O	O
degrees	O	O
C	O	O
,	O	O
to	O	O
5	O	O
mM	O	O
levels	O	O
of	O	O
28	O	O
ATP	O	O
derivatives	O	O
.	O	O
For	O	O
example	O	O
,	O	O
the	O	O
most	O	O
potent	O	O
derivative	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphtho	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
with	O	O
an	O	O
IC50	O	O
of	O	O
0.020	O	O
microM	O	O
,	O	O
is	O	O
as	O	O
potent	O	O
as	O	O
sorbinil	O	O
(	O	O
IC50	O	O
=	O	O
0.017	O	O
microM	O	O
)	O	O
in	O	O
the	O	O
crude	O	O
rat	O	O
lens	O	O
aldose	O	O
reductase	O	O
assay	O	O
.	O	O
The	O	O
observed	O	O
order	O	O
of	O	O
activity	O	O
was	O	O
3d	O	O
greater	O	O
than	O	O
3c	O	O
greater	O	O
than	O	O
3b	O	O
greater	O	O
than	O	O
3a	O	O
.	O	O
Treatment	O	O
of	O	O
thymidine	O	O
with	O	O
trimethylsilyl	O	O
chloride	O	O
and	O	O
then	O	O
with	O	O
phosphoryl	O	O
chloride	O	O
and	O	O
1,2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
gave	O	O
upon	O	O
workup	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
The	O	O
radioiodinations	O	O
of	O	O
all	O	O
compounds	O	O
with	O	O
[	O	O
(	O	O
131	O	O
)	O	O
I	O	O
]	O	O
I	O	O
(	O	O
-	O	O
)	O	O
were	O	O
performed	O	O
with	O	O
radiochemical	O	O
yields	O	O
of	O	O
&	O	O
gt	O	O
;	O	O
70%	O	O
for	O	O
the	O	O
destannylation	O	O
of	O	O
the	O	O
corresponding	O	O
tri	O	O
-	O	O
n	O	O
-	O	O
butylstannylated	O	O
precursors	O	O
.	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylpiperazinopropylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
(	O	O
20	O	O
)	O	O
behaved	O	O
like	O	O
an	O	O
agonist	O	O
of	O	O
presynaptic	O	O
and	O	O
as	O	O
a	O	O
partial	O	O
agonist	O	O
of	O	O
postsynaptic	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptors	O	O
and	O	O
resembled	O	O
ipsapirone	O	O
in	O	O
terms	O	O
of	O	O
functional	O	O
intrinsic	O	O
activity	O	O
.	O	O
With	O	O
only	O	O
one	O	O
exception	O	O
,	O	O
methyl	B-IUPAC	B-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
,	O	O
both	O	O
classes	O	O
of	O	O
compounds	O	O
exhibited	O	O
similar	O	O
activity	O	O
vs.	O	O
Nematospiroides	O	O
dubius	O	O
in	O	O
mice	O	O
.	O	O
In	O	O
the	O	O
present	O	O
work	O	O
,	O	O
we	O	O
describe	O	O
how	O	O
the	O	O
bicyclo	B-IUPAC	O
[	I-IUPAC	O
3.1.0	I-IUPAC	O
]	I-IUPAC	O
hexane	I-IUPAC	O
template	O	O
fixes	O	O
the	O	O
ring	O	O
pucker	O	O
of	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methanocarba	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nucleosides	I-IUPAC	I-IUPAC
1-5	O	O
and	O	O
12	O	O
to	O	O
values	O	O
corresponding	O	O
to	O	O
either	O	O
one	O	O
of	O	O
these	O	O
two	O	O
extreme	O	O
conformations	O	O
that	O	O
are	O	O
typical	O	O
of	O	O
nucleosides	O	O
.	O	O
The	O	O
1	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
butyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	O
(	O	O
37	O	O
and	O	O
39	O	O
)	O	O
and	O	O
1	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methoxyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
(	O	O
38	O	O
and	O	O
40	O	O
)	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyluracils	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
by	O	O
1	O	O
-	O	O
alkylation	O	O
of	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenacyl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
35	O	O
and	O	O
36	O	O
with	O	O
alkyl	O	O
halides	O	O
followed	O	O
by	O	O
deprotection	O	O
of	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenacyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
.	O	O
None	O	O
of	O	O
the	O	O
compounds	O	O
was	O	O
as	O	O
potent	O	O
as	O	O
TMQ	O	O
or	O	O
PTX	O	O
,	O	O
and	O	O
while	O	O
some	O	O
of	O	O
them	O	O
showed	O	O
some	O	O
selectivity	O	O
in	O	O
their	O	O
binding	O	O
to	O	O
Pneumocystis	O	O
carinii	O	O
and	O	O
Toxoplasma	O	O
gondii	O	O
versus	O	O
rat	O	O
liver	O	O
DHFR	O	O
,	O	O
this	O	O
effect	O	O
was	O	O
not	O	O
deemed	O	O
large	O	O
enough	O	O
to	O	O
warrant	O	O
further	O	O
preclinical	O	O
evaluation	O	O
.	O	O
The	O	O
activity	O	O
profiles	O	O
of	O	O
5k	O	O
,	O	O
l	O	O
were	O	O
generally	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
5j	O	O
except	O	O
that	O	O
there	O	O
were	O	O
no	O	O
cells	O	O
against	O	O
which	O	O
the	O	O
IC50	O	O
was	O	O
&	O	O
lt	O	O
;	O	O
0.01	O	O
microM	O	O
.	O	O
For	O	O
the	O	O
ketones	O	O
,	O	O
the	O	O
order	O	O
is	O	O
24	O	O
-	O	O
one	O	O
&	O	O
gt	O	O
;	O	O
or	O	O
=	O	O
23	O	B-IUPAC
-	O	I-IUPAC
one	O	I-IUPAC
&	O	O
gt	O	O
;	O	O
20	O	B-IUPAC
-	O	I-IUPAC
one	O	I-IUPAC
&	O	O
gt	O	O
;	O	O
22	O	B-IUPAC
-	O	I-IUPAC
one	O	I-IUPAC
.	O	O
Size	O	O
and	O	O
planarity	O	O
of	O	O
the	O	O
aromatic	O	O
side	O	O
chain	O	O
were	O	O
crucially	O	O
important	O	O
for	O	O
the	O	O
biological	O	O
activity	O	O
,	O	O
whereas	O	O
electron	O	O
-	O	O
donating	O	O
and	O	O
electron	O	O
-	O	O
withdrawing	O	O
properties	O	O
of	O	O
the	O	O
para	O	O
-	O	O
substituent	O	O
were	O	O
less	O	O
important	O	O
.	O	O
Compound	O	O
1a	O	O
,	O	O
the	O	O
most	O	O
potent	O	O
isomer	O	O
of	O	O
the	O	O
series	O	O
,	O	O
was	O	O
also	O	O
tested	O	O
in	O	O
vivo	O	O
on	O	O
pithed	O	O
rat	O	O
and	O	O
its	O	O
muscarinic	O	O
activity	O	O
at	O	O
the	O	O
M1	O	O
receptor	O	O
subtype	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
muscarine	O	O
.	O	O
Affinity	O	O
at	O	O
the	O	O
H2	O	O
receptors	O	O
,	O	O
evaluated	O	O
from	O	O
antagonism	O	O
of	O	O
histamine	O	O
-	O	O
stimulated	O	O
chronotropic	O	O
response	O	O
on	O	O
guinea	O	O
pig	O	O
atria	O	O
,	O	O
increased	O	O
following	O	O
fluorine	O	O
substitution	O	O
(	O	O
3a	O	O
,	O	O
KB	O	O
=	O	O
177	O	O
;	O	O
3b	O	O
,	O	O
KB	O	O
=	O	O
61	O	O
;	O	O
3c	O	O
,	O	O
KB	O	O
=	O	O
21	O	O
;	O	O
3d	O	O
,	O	O
KB	O	O
=	O	O
7.6	O	O
)	O	O
.	O	O
Preferred	O	O
substituents	O	O
on	O	O
the	O	O
triazolinone	O	O
ring	O	O
were	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
at	O	O
C5	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
at	O	O
N2	O	O
.	O	O
A	O	O
potent	O	O
and	O	O
orally	O	O
active	O	O
NK1	O	O
antagonist	O	O
,	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
1t	O	O
)	O	O
,	O	O
was	O	O
shown	O	O
to	O	O
exist	O	O
as	O	O
a	O	O
mixture	O	O
of	O	O
separable	O	O
and	O	O
stable	O	O
(	O	O
R	O	O
)	O	O
-	O	O
and	O	O
(	O	O
S	O	O
)	O	O
-	O	O
atropisomers	O	O
(	O	O
1t	O	O
-	O	O
A	O	O
and	O	O
1t	O	O
-	O	O
B	O	O
)	O	O
originating	O	O
from	O	O
the	O	O
restricted	O	O
rotation	O	O
around	O	O
the	O	O
-	O	O
C	O	O
(	O	O
6	O	O
)	O	O
-	O	O
C	O	O
(	O	O
=	O	O
O	O	O
)	O	O
-	O	O
bond	O	O
;	O	O
the	O	O
antagonistic	O	O
activities	O	O
of	O	O
1t	O	O
-	O	O
A	O	O
were	O	O
ca.	O	O
6-13	O	O
-	O	O
fold	O	O
higher	O	O
than	O	O
those	O	O
of	O	O
1t	O	O
-	O	O
B	O	O
.	O	O
The	O	O
activity	O	O
of	O	O
13	O	O
against	O	O
P	O	O
.	O	O
Chemical	O	O
functionality	O	O
incorporated	O	O
in	O	O
the	O	O
thioether	O	O
moiety	O	O
included	O	O
cyanoalkyl	O	O
,	O	O
nitroaromatic	O	O
,	O	O
amino	B-IUPAC	B-IUPAC
,	O	O
thiol	B-IUPAC	O
,	O	O
cycloalkyl	O	B-IUPAC
,	O	O
n	O	B-IUPAC
-	O	I-IUPAC
alkyl	O	I-IUPAC
,	O	O
and	O	O
olefinic	O	O
groups	O	O
.	O	O
The	O	O
five	O	O
acids	O	O
are	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorobenzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
FB	O	O
,	O	O
2b	O	O
)	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
MeFB	O	O
,	O	O
2c	O	O
)	O	O
,	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorocyclohexanecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
FC	O	O
,	O	O
2d	O	O
)	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
FMeB	O	O
,	O	O
2e	O	O
)	O	O
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
NFMeB	O	O
,	O	O
2f	O	O
)	O	O
(	O	O
see	O	O
Scheme	O	O
1	O	O
)	O	O
.	O	O
Even	O	O
though	O	O
8a	O	O
and	O	O
8b	O	O
were	O	O
found	O	O
to	O	O
be	O	O
curative	O	O
in	O	O
a	O	O
high	O	O
percentage	O	O
of	O	O
mice	O	O
bearing	O	O
ip	O	O
implanted	O	O
partially	O	O
ara	O	O
-	O	O
C	O	O
resistant	O	O
L1210	O	O
subline	O	O
[	O	O
L1210	O	O
/	O	O
ara	O	O
-	O	O
C	O	O
(	O	O
I	O	O
)	O	O
]	O	O
,	O	O
they	O	O
were	O	O
completely	O	O
ineffective	O	O
against	O	O
deoxycytidine	O	O
kinase	O	O
deficient	O	O
ara	O	O
-	O	O
C	O	O
resistant	O	O
L1210	O	O
subline	O	O
[	O	O
L1210	O	O
/	O	O
ara	O	O
-	O	O
C	O	O
(	O	O
II	O	O
)	O	O
]	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
derivatives	O	O
39	O	O
,	O	O
46	O	O
,	O	O
and	O	O
61	O	O
bound	O	O
with	O	O
higher	O	O
affinity	O	O
and	O	O
selectivity	O	O
to	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
(	O	O
versus	O	O
dopaminergic	O	O
D2	O	O
and	O	O
adrenergic	O	O
alpha1	O	O
receptors	O	O
)	O	O
and	O	O
displayed	O	O
more	O	O
potent	O	O
5	O	O
-	O	O
HT1A	O	O
agonist	O	O
activity	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
than	O	O
their	O	O
C	O	O
-	O	O
4	O	O
desfluoro	O	O
analogues	O	O
.	O	O
Three	O	O
were	O	O
bromoacetamides	O	O
differing	O	O
at	O	O
the	O	O
alkyl	O	O
substituent	O	O
(	O	O
methyl	O	B-IUPAC
,	O	O
ethyl	O	B-IUPAC
,	O	O
or	O	O
propyl	O	B-PARTIUPAC
)	O	O
,	O	O
and	O	O
the	O	O
last	O	O
was	O	O
an	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
iodoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
prepared	O	O
under	O	O
both	O	O
nonradioactive	O	O
and	O	O
3H	O	O
-	O	O
labeled	O	O
forms	O	O
.	O	O
Deprotection	O	O
of	O	O
18	O	O
with	O	O
tetra	B-IUPAC	O
-	I-IUPAC	O
n	I-IUPAC	O
-	I-IUPAC	O
butylammonium	I-IUPAC	O
fluoride	I-IUPAC	O
and	O	O
ring	O	O
annulation	O	O
with	O	O
hydrazine	O	O
afforded	O	O
20	O	O
.	O	O
It	O	O
is	O	O
interesting	O	O
to	O	O
note	O	O
that	O	O
the	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
exhibited	O	O
an	O	O
excellent	O	O
anti	O	O
-	O	O
HIV	O	O
activity	O	O
(	O	O
EC50	O	O
=	O	O
0.063	O	O
microM	O	O
)	O	O
without	O	O
cytotoxicity	O	O
up	O	O
to	O	O
100	O	O
microM	O	O
in	O	O
PBM	O	O
cell	O	O
.	O	O
Conversion	O	O
to	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
and	O	O
condensation	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloroaniline	I-IUPAC	I-IUPAC
gave	O	O
the	O	O
corresponding	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
[	O	O
125I	O	O
]	O	O
-	O	O
radiolabeled	O	O
congeners	O	O
of	O	O
10	O	O
and	O	O
14	O	O
were	O	O
prepared	O	O
as	O	O
potential	O	O
metabolic	O	O
markers	O	O
.	O	O
This	O	O
compound	O	O
is	O	O
1'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
spiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
,	O	O
14f	O	O
(	O	O
code	O	O
no	O	O
.	O	O
Because	O	O
of	O	O
the	O	O
high	O	O
potency	O	O
and	O	O
selectivity	O	O
of	O	O
19	O	O
,	O	O
this	O	O
compound	O	O
has	O	O
also	O	O
been	O	O
prepared	O	O
in	O	O
the	O	O
[	O	O
125I	O	O
]	O	O
-	O	O
iodinated	O	O
form	O	O
by	O	O
a	O	O
nucleophilic	O	O
halogen	O	O
exchange	O	O
reaction	O	O
using	O	O
the	O	O
corresponding	O	O
bromo	O	O
derivative	O	O
22	O	O
as	O	O
a	O	O
precursor	O	O
.	O	O
The	O	O
same	O	O
phenomenon	O	O
had	O	O
been	O	O
observed	O	O
for	O	O
the	O	O
DENSPM	O	O
/	O	O
(	O	O
2R	O	O
,	O	O
10R	O	O
)	O	O
-	O	O
(	O	O
HO	O	O
)	O	O
(	O	O
2	O	O
)	O	O
DENSPM	O	O
pair	O	O
.	O	O
The	O	O
N	O	O
(	O	O
1	O	O
)	O	O
-	O	O
substituents	O	O
included	O	O
benzyl	B-IUPAC	O
,	O	O
naphthalen	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
,	O	O
anthracen	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
pyren	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
.	O	O
The	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
and	O	O
the	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
10b	O	O
,	O	O
f	O	O
have	O	O
demonstrated	O	O
high	O	O
potency	O	O
(	O	O
0.4	O	O
and	O	O
0.3	O	O
microM	O	O
)	O	O
and	O	O
excellent	O	O
selectivity	O	O
(	O	O
HCR	O	O
=	O	O
250	O	O
and	O	O
340	O	O
)	O	O
.	O	O
LiAlH4	O	O
reduction	O	O
of	O	O
3	O	O
gave	O	O
9,11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
seco	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyestradiol	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ether	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
which	O	O
on	O	O
demethylation	O	O
gave	O	O
9,11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
seco	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyestradiol	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
.	O	O
Two	O	O
examples	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dicyanoimidazole	I-IUPAC	I-IUPAC
(	O	O
16	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroimidazole	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
were	O	O
at	O	O
least	O	O
an	O	O
order	O	O
of	O	O
magnitude	O	O
more	O	O
active	O	O
than	O	O
the	O	O
standards	O	O
and	O	O
therefore	O	O
rank	O	O
among	O	O
the	O	O
most	O	O
potent	O	O
known	O	O
inhibitors	O	O
of	O	O
the	O	O
enzyme	O	O
.	O	O
Desulfurization	O	O
of	O	O
these	O	O
thioureas	O	O
by	O	O
Raney	O	O
nickel	O	O
furnished	O	O
the	O	O
desired	O	O
formamidines	O	O
(	O	O
3b	O	O
-	O	O
d	O	O
)	O	O
.	O	O
The	O	O
results	O	O
obtained	O	O
through	O	O
site	O	O
-	O	O
directed	O	O
mutagenic	O	O
analysis	O	O
support	O	O
our	O	O
predicted	O	O
binding	O	O
models	O	O
for	O	O
these	O	O
ligands	O	O
and	O	O
provide	O	O
new	O	O
insights	O	O
into	O	O
PKC	O	O
-	O	O
ligand	O	O
binding	O	O
.	O	O
Vasotocin	O	O
(	O	O
AVT	O	O
)	O	O
analogues	O	O
with	O	O
tyrosine	O	O
or	O	O
phenylalanine	O	O
in	O	O
position	O	O
9	O	O
,	O	O
i.e.	O	O
,	O	O
[	O	B-IUPAC
9	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosine	I-IUPAC	I-IUPAC
]	O	I-IUPAC
AVT	O	I-IUPAC
,	O	I-IUPAC
[	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylalanine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosine	I-IUPAC	I-IUPAC
]	O	O
AVT	O	O
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desamino	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenylalanine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	O
AVT	O	O
,	O	O
were	O	O
synthesized	O	O
by	O	O
the	O	O
solid	O	O
-	O	O
phase	O	O
method	O	O
.	O	O
For	O	O
the	O	O
preparation	O	O
of	O	O
5e	O	O
a	O	O
new	O	O
ring	O	O
-	O	O
closure	O	O
method	O	O
was	O	O
applied	O	O
.	O	O
HPLC	O	O
analyses	O	O
and	O	O
circular	O	O
dichroism	O	O
spectroscopy	O	O
indicated	O	O
the	O	O
absolute	O	O
stereochemistry	O	O
of	O	O
8	O	O
and	O	O
9	O	O
to	O	O
be	O	O
S	O	O
and	O	O
R	O	O
,	O	O
respectively	O	O
.	O	O
After	O	O
selective	O	O
tritylation	O	O
of	O	O
the	O	O
tetrazole	O	O
rings	O	O
in	O	O
3	O	O
and	O	O
4	O	O
,	O	O
treatment	O	O
of	O	O
N	B-MODIFIER	B-IUPAC
-	I-MODIFIER	I-IUPAC
tritylated	I-MODIFIER	I-IUPAC
benzimidazole	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
(	O	O
6	O	O
,	O	O
7	O	O
)	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
alkyl	O	O
halides	O	O
,	O	O
followed	O	O
by	O	O
deprotection	O	O
with	O	O
hydrochloric	O	O
acid	O	O
,	O	O
afforded	O	O
esters	O	O
of	O	O
3	O	O
and	O	O
4	O	O
.	O	O
Biol.	O	O
Chem.	O	O
1983	O	O
,	O	O
258	O	O
,	O	O
15046-15053	O	O
.	O	O
Compound	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
is	O	O
the	O	O
most	O	O
selective	O	O
of	O	O
this	O	O
group	O	O
(	O	O
16	O	O
-	O	O
fold	O	O
)	O	O
for	O	O
the	O	O
sigma	O	O
1	O	O
subtype	O	O
versus	O	O
sigma	O	O
2	O	O
.	O	O
All	O	O
the	O	O
new	O	O
synthesized	O	O
pyrimidines	O	O
were	O	O
evaluated	O	O
in	O	O
spontaneously	O	O
beating	O	O
and	O	O
electrically	O	O
driven	O	O
atria	O	O
from	O	O
reserpine	O	O
-	O	O
treated	O	O
guinea	O	O
pigs	O	O
.	O	O
The	O	O
NAD	O	O
analogue	O	O
23b	O	O
was	O	O
also	O	O
prepared	O	O
by	O	O
the	O	O
treatment	O	O
of	O	O
17	O	O
with	O	O
an	O	O
activated	O	O
form	O	O
of	O	O
AMP	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
AgNO3	O	O
.	O	O
Molecular	O	O
modeling	O	O
studies	O	O
show	O	O
that	O	O
the	O	O
4	O	B-IUPAC
-	O	I-IUPAC
carbonyl	O	I-IUPAC
groups	O	B-MODIFIER
of	O	O
the	O	O
kynurenic	O	O
acids	O	O
,	O	O
the	O	O
tetrahydroquinolines	O	O
,	O	O
and	O	O
related	O	O
antagonists	O	O
based	O	O
on	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
glycine	I-IUPAC	I-IUPAC
,	O	O
can	O	O
interact	O	O
with	O	O
a	O	O
single	O	O
putative	O	O
H	O	O
-	O	O
bond	O	O
donor	O	O
on	O	O
the	O	O
receptor	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
designed	O	O
as	O	O
potential	O	O
ACE	O	O
inhibitors	O	O
of	O	O
novel	O	O
structure	O	O
,	O	O
assuming	O	O
that	O	O
a	O	O
monoamidic	O	O
residue	O	O
of	O	O
an	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclomethylenedicarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
could	O	O
be	O	O
an	O	O
alternative	O	O
structure	O	O
to	O	O
the	O	O
acylproline	O	O
moiety	O	O
,	O	O
the	O	O
carboxyl	O	O
-	O	O
terminal	O	O
portion	O	O
common	O	O
to	O	O
various	O	O
ACE	O	O
inhibitors	O	O
.	O	O
Conformational	O	O
analyses	O	O
show	O	O
that	O	O
these	O	O
isomers	O	O
exist	O	O
in	O	O
a	O	O
flattened	O	O
boat	O	O
conformation	O	O
with	O	O
pseudoequatorial	O	O
substituents	O	O
.	O	O
The	O	O
thermal	O	O
Fischer	O	O
indolization	O	O
of	O	O
hydrazones	O	O
resulting	O	O
from	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydrazino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
and	O	O
various	O	O
beta	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
alpha	B-IUPAC	O
-	I-IUPAC	O
tetralones	I-IUPAC	O
led	O	O
to	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
g	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
The	O	O
observed	O	O
lower	O	O
cytotoxicity	O	O
in	O	O
the	O	O
PAT	O	O
-	O	O
deficient	O	O
CHO	O	O
-	O	O
MG	O	O
cell	O	O
line	O	O
supported	O	O
the	O	O
premise	O	O
that	O	O
the	O	O
conjugates	O	O
use	O	O
PAT	O	O
for	O	O
cellular	O	O
entry	O	O
.	O	O
Many	O	O
compounds	O	O
within	O	O
this	O	O
piperazine	O	O
series	O	O
of	O	O
[	B-IUPAC	B-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazine	I-IUPAC	I-IUPAC
have	O	O
now	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
good	O	O
oral	O	O
bioavailability	O	O
in	O	O
the	O	O
rat	O	O
,	O	O
with	O	O
some	O	O
as	O	O
high	O	O
as	O	O
89%	O	O
(	O	O
compound	O	O
35	O	O
)	O	O
.	O	O
TFPe	O	O
-	O	O
dUrd	O	O
demonstrated	O	O
a	O	O
potent	O	O
and	O	O
unusually	O	O
selective	O	O
activity	O	O
against	O	O
HSV	O	O
-	O	O
1	O	O
,	O	O
with	O	O
a	O	O
2	O	O
-	O	O
log	O	O
reduction	O	O
in	O	O
virus	O	O
yield	O	O
at	O	O
0.03	O	O
micrograms	O	O
/	O	O
mL	O	O
(	O	O
0.09	O	O
microM	O	O
)	O	O
;	O	O
L	O	O
-	O	O
1210	O	O
cell	O	O
growth	O	O
was	O	O
inhibited	O	O
by	O	O
50%	O	O
only	O	O
at	O	O
290	O	O
micrograms	O	O
/	O	O
mL	O	O
.	O	O
Compound	O	O
7n	O	O
is	O	O
a	O	O
13	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
inhibitor	O	O
than	O	O
7b	O	O
,	O	O
and	O	O
these	O	O
kinetic	O	O
studies	O	O
indicate	O	O
that	O	O
the	O	O
increase	O	O
in	O	O
inhibitory	O	O
activity	O	O
is	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
initial	O	O
affinity	O	O
toward	O	O
the	O	O
enzyme	O	O
and	O	O
not	O	O
an	O	O
increase	O	O
in	O	O
chemical	O	O
reactivity	O	O
.	O	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
Nitrobenzene	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorobenzenesulfonamides	I-IUPAC	I-IUPAC
containing	O	O
both	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
substituents	B-MODIFIER	B-MODIFIER
were	O	O
model	O	O
irreversible	O	O
inhibitors	O	O
of	O	O
carbonic	O	O
anhydrase	O	O
and	O	O
exhibited	O	O
a	O	O
trend	O	O
toward	O	O
topical	O	O
activity	O	O
in	O	O
reducing	O	O
IOP	O	O
in	O	O
normotensive	O	O
rabbit	O	O
eyes	O	O
.	O	O
Inhibition	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
AMPA	O	O
binding	O	O
by	O	O
ATPA	O	O
was	O	O
1	O	O
order	O	O
of	O	O
magnitude	O	O
weaker	O	O
than	O	O
that	O	O
of	O	O
AMPA	O	O
,	O	O
in	O	O
agreement	O	O
with	O	O
the	O	O
relative	O	O
potency	O	O
of	O	O
these	O	O
compounds	O	O
in	O	O
vivo	O	O
.	O	O
Thrombin	O	O
is	O	O
a	O	O
serine	O	O
protease	O	O
responsible	O	O
for	O	O
blood	O	O
coagulation	O	O
.	O	O
A	O	O
novel	O	O
reagent	O	O
,	O	O
maleimidoethyl	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylstannyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
hippurate	I-IUPAC	I-IUPAC
(	O	O
MIH	O	O
)	O	O
,	O	O
was	O	O
synthesized	O	O
by	O	O
reacting	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
maleimide	I-IUPAC	I-IUPAC
with	O	O
N	B-IUPAC	O
-	I-IUPAC	O
Boc	I-IUPAC	O
-	I-IUPAC	O
glycine	I-IUPAC	O
before	O	O
coupling	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
succinimidyl	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylstannyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
ATE	O	O
)	O	O
.	O	O
However	O	O
,	O	O
oral	O	O
activity	O	O
in	O	O
the	O	O
PAF	O	O
-	O	O
induced	O	O
bronchoconstriction	O	O
model	O	O
was	O	O
highly	O	O
sensitive	O	O
to	O	O
the	O	O
nature	O	O
and	O	O
substitution	O	O
of	O	O
the	O	O
bicyclic	O	O
ring	O	O
system	O	O
.	O	O
A	O	O
3	O	O
-	O	O
substituent	O	O
on	O	O
the	O	O
piperidine	O	O
ring	O	O
was	O	O
necessary	O	O
for	O	O
antiplatelet	O	O
activity	O	O
;	O	O
the	O	O
substituent	O	O
should	O	O
be	O	O
preferably	O	O
an	O	O
amide	O	O
with	O	O
its	O	O
C	O	O
attached	O	O
directly	O	O
to	O	O
the	O	O
ring	O	O
.	O	O
Synthesis	O	O
and	O	O
biological	O	O
activities	O	O
of	O	O
12	O	O
analogs	O	O
of	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyladenosine	I-IUPAC	I-IUPAC
are	O	O
described	O	O
.	O	O
In	O	O
general	O	O
,	O	O
the	O	O
derivatives	O	O
were	O	O
found	O	O
to	O	O
be	O	O
considerably	O	O
more	O	O
potent	O	O
at	O	O
24	O	O
h	O	O
than	O	O
at	O	O
2	O	O
h	O	O
after	O	O
the	O	O
administration	O	O
.	O	O
The	O	O
order	O	O
of	O	O
efficiency	O	O
was	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
bromoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
&	O	O
lt	O	O
;	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
bromoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
&	O	O
lt	O	O
;	O	O
&	O	O
lt	O	O
;	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
bromoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
&	O	O
lt	O	O
;	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
iodoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
.	O	O
In	O	O
this	O	O
case	O	O
,	O	O
both	O	O
cis	O	O
and	O	O
trans	O	O
isomers	O	O
showed	O	O
equally	O	O
weak	O	O
in	O	O
vitro	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
agonist	O	O
activity	O	O
devoid	O	O
of	O	O
dopaminergic	O	O
effects	O	O
.	O	O
In	O	O
general	O	O
,	O	O
compounds	O	O
having	O	O
two	O	O
different	O	O
R1	O	O
and	O	O
R2	O	O
substituents	O	O
in	O	O
the	O	O
4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolane	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
were	O	O
more	O	O
water	O	O
-	O	O
soluble	O	O
than	O	O
those	O	O
having	O	O
the	O	O
same	O	O
substituents	O	O
.	O	O
The	O	O
diphenylmethyl	O	B-IUPAC
moiety	O	B-MODIFIER
functioned	O	O
as	O	O
an	O	O
effective	O	O
isostere	O	O
for	O	O
4,5	O	O
-	O	O
diphenylated	O	O
heterocycles	O	O
since	O	O
13aad	O	O
showed	O	O
similar	O	O
platelet	O	O
inhibitory	O	O
activity	O	O
to	O	O
3	O	O
.	O	O
Most	O	O
members	O	O
of	O	O
this	O	O
series	O	O
showed	O	O
the	O	O
excellent	O	O
antitumor	O	O
activity	O	O
against	O	O
murine	O	O
L1210	O	O
leukemia	O	O
cells	O	O
transplanted	O	O
in	O	O
mice	O	O
and	O	O
were	O	O
superior	O	O
to	O	O
cisplatin	O	O
and	O	O
carboplatin	O	O
.	O	O
5	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
Piperidyl	O	I-IUPAC
)	O	I-IUPAC
isoxazol	O	I-IUPAC
-	O	I-IUPAC
3	O	I-IUPAC
-	O	I-IUPAC
ol	O	I-IUPAC
(	O	O
4	O	O
-	O	O
PIOL	O	O
,	O	O
10	O	O
)	O	O
,	O	O
a	O	O
structural	O	O
analog	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminobutanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
GABA	O	O
,	O	O
1	O	O
)	O	O
and	O	O
the	O	O
GABAA	O	O
agonist	O	O
4,5,6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoxazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
THIP	O	O
,	O	O
5	O	O
)	O	O
,	O	O
is	O	O
a	O	O
low	O	O
-	O	O
efficacy	O	O
partial	O	O
GABAA	O	O
agonist	O	O
.	O	O
The	O	O
resulting	O	O
diastereoisomers	O	O
were	O	O
separated	O	O
by	O	O
column	O	O
chromatography	O	O
and	O	O
their	O	O
structures	O	O
established	O	O
by	O	O
CD	O	O
and	O	O
NMR	O	O
spectroscopy	O	O
.	O	O
Quantitative	O	O
autoradiographic	O	O
techniques	O	O
were	O	O
utilized	O	O
in	O	O
regional	O	O
analyses	O	O
of	O	O
antagonist	O	O
binding	O	O
.	O	O
A	O	O
series	O	O
of	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
formylpyridine	I-IUPAC	I-IUPAC
thiosemicarbazones	I-IUPAC	I-IUPAC
has	O	O
been	O	O
synthesized	O	O
which	O	O
contain	O	O
a	O	O
tertiary	O	O
N	O	O
at	O	O
the	O	O
4	O	O
position	O	O
.	O	O
Three	O	O
electrophilic	O	O
amide	O	O
analogues	O	O
of	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminopropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
1	O	O
,	O	O
DAP	O	O
)	O	O
have	O	O
been	O	O
prepared	O	O
as	O	O
potential	O	O
inhibitors	O	O
of	O	O
L	O	O
-	O	O
asparagine	O	O
synthetase	O	O
(	O	O
ASase	O	O
,	O	O
from	O	O
Novikoff	O	O
hepatoma	O	O
,	O	O
EC	O	O
6.3.5.4	O	O
)	O	O
.	O	O
Thermal	O	O
decomposition	O	O
of	O	O
9b	O	O
and	O	O
9c	O	O
at	O	O
110	O	O
degrees	O	O
C	O	O
in	O	O
dioxane	O	O
yielded	O	O
corresponding	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azirinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
(	O	O
10b	O	O
,	O	O
c	O	O
)	O	O
.	O	O
The	O	O
somatostatin	O	O
receptor	O	O
binding	O	O
affinities	O	O
of	O	O
synthetic	O	O
DTPA	O	O
-	O	O
D	O	O
-	O	O
Phe1	O	O
-	O	O
octreotide	O	O
and	O	O
CPTA	O	O
-	O	O
D	O	O
-	O	O
Phe1	O	O
-	O	O
octreotide	O	O
to	O	O
AtT	O	O
-	O	O
20	O	O
mouse	O	O
pituitary	O	O
carcinoma	O	O
cell	O	O
membranes	O	O
were	O	O
examined	O	O
by	O	O
labeling	O	O
with	O	O
111In	O	O
and	O	O
64Cu	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
performing	O	O
Scatchard	O	O
analyses	O	O
.	O	O
Some	O	O
of	O	O
the	O	O
7	O	O
-	O	O
oxa	O	O
-	O	O
7,8	O	O
-	O	O
dihydro	O	O
-	O	O
RAs	O	O
bind	O	O
to	O	O
CRABP	O	O
and	O	O
RARalpha	O	O
.	O	O
The	O	O
in	O	O
vitro	O	O
inotropic	O	O
activity	O	O
of	O	O
these	O	O
compounds	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
known	O	O
cardiotonics	O	O
amrinone	O	O
and	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxycyclindole	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
was	O	O
investigated	O	O
.	O	O
The	O	O
most	O	O
interesting	O	O
compounds	O	O
included	O	O
[	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenamide	I-IUPAC	I-IUPAC
(	O	O
4b	O	O
)	O	O
,	O	O
[	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiophene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenamide	I-IUPAC	I-IUPAC
(	O	O
4k	O	O
)	O	O
,	O	O
and	O	O
[	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indoly	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenamide	I-IUPAC	I-IUPAC
(	O	O
4l	O	O
)	O	O
which	O	O
inhibited	O	O
PAF	O	O
-	O	O
induced	O	O
broncho	O	O
-	O	O
constriction	O	O
in	O	O
guinea	O	O
pigs	O	O
with	O	O
IC50s	O	O
of	O	O
3.0-5.4	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
when	O	O
the	O	O
animals	O	O
were	O	O
challenged	O	O
2	O	O
h	O	O
after	O	O
drug	O	O
treatment	O	O
.	O	O
As	O	O
the	O	O
most	O	O
effective	O	O
route	O	O
,	O	O
Newman	O	O
-	O	O
Kwart	O	O
rearrangement	O	O
of	O	O
benzazocines	O	O
was	O	O
selected	O	O
and	O	O
closely	O	O
investigated	O	O
.	O	O
The	O	O
results	O	O
revealed	O	O
that	O	O
the	O	O
H4a	O	O
,	O	O
H5	O	O
-	O	O
cis	O	O
,	O	O
H4a	O	O
,	O	O
H9b	O	O
-	O	O
cis	O	O
series	O	O
and	O	O
the	O	O
ortho	O	B-IUPAC
-	O	O
substituted	O	B-MODIFIER
5	O	B-IUPAC
-	O	I-IUPAC
phenyl	O	I-IUPAC
H4a	O	O
,	O	O
H5	O	O
-	O	O
trans	O	O
,	O	O
H4a	O	O
,	O	O
H9b	O	O
-	O	O
cis	O	O
compounds	O	O
lack	O	O
activity	O	O
.	O	O
In	O	O
functional	O	O
selectivity	O	O
experiments	O	O
,	O	O
10	O	O
,	O	O
13	O	O
,	O	O
and	O	O
14	O	O
did	O	O
not	O	O
stimulate	O	O
H	O	O
(	O	O
2	O	O
)	O	O
,	O	O
H	O	O
(	O	O
3	O	O
)	O	O
,	O	O
and	O	O
several	O	O
other	O	O
neurotransmitter	O	O
receptors	O	O
.	O	O
The	O	O
object	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
structural	O	O
factors	O	O
governing	O	O
sigma	O	O
1	O	O
/	O	O
sigma	O	O
2	O	O
affinity	O	O
and	O	O
selectivity	O	O
within	O	O
this	O	O
class	O	O
of	O	O
compounds	O	O
.	O	O
Their	O	O
inhibitory	O	O
effect	O	O
on	O	O
AII	O	O
-	O	O
induced	O	O
pressor	O	O
response	O	O
in	O	O
rats	O	O
and	O	O
oral	O	O
BA	O	O
were	O	O
investigated	O	O
.	O	O
None	O	O
of	O	O
the	O	O
new	O	O
compounds	O	O
were	O	O
estrogenic	O	O
in	O	O
the	O	O
3	O	O
-	O	O
day	O	O
immature	O	O
mouse	O	O
uterotrophic	O	O
assay	O	O
at	O	O
doses	O	O
up	O	O
to	O	O
750	O	O
micrograms	O	O
.	O	O
Given	O	O
significant	O	O
binding	O	O
to	O	O
one	O	O
or	O	O
more	O	O
EAA	O	O
receptors	O	O
,	O	O
5	O	O
would	O	O
offer	O	O
unique	O	O
modeling	O	O
and	O	O
perhaps	O	O
biological	O	O
opportunities	O	O
.	O	O
In	O	O
comparison	O	O
to	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
androstane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
4	O	O
-	O	O
MA	O	O
;	O	O
IC50	O	O
=	O	O
4.15	O	O
nM	O	O
)	O	O
,	O	O
17	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylformamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azasteroids	I-IUPAC	I-IUPAC
were	O	O
potent	O	O
inhibitors	O	O
of	O	O
human	O	O
type	O	O
I	O	O
5	O	O
alpha	O	O
-	O	O
reductase	O	O
,	O	O
IC50	O	O
values	O	O
of	O	O
compounds	O	O
29	O	O
,	O	O
30	O	O
,	O	O
36	O	O
,	O	O
and	O	O
37	O	O
being	O	O
measured	O	O
as	O	O
3.05	O	O
,	O	O
0.91	O	O
,	O	O
2.19	O	O
,	O	O
and	O	O
2.35	O	O
nM	O	O
,	O	O
respectively	O	O
.	O	O
They	O	O
also	O	O
demonstrated	O	O
high	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
site	O	O
(	O	O
Ki	O	O
=	O	O
10	O	O
nM	O	O
)	O	O
and	O	O
exhibited	O	O
partial	O	O
agonist	O	O
/	O	O
antagonist	O	O
activity	O	O
in	O	O
the	O	O
serotonin	O	O
syndrome	O	O
test	O	O
.	O	O
Ring	O	O
closure	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethanone	I-IUPAC	I-IUPAC
dihydrochloride	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
with	O	O
triethyl	B-IUPAC	O
orthoacetate	I-IUPAC	O
or	O	O
triethyl	B-IUPAC	O
orthopropionate	I-IUPAC	O
gave	O	O
the	O	O
C	B-MODIFIER	O
-	I-MODIFIER	O
5	I-MODIFIER	O
methyl	B-IUPAC	O
and	O	O
ethyl	B-IUPAC	B-IUPAC
ketoaglycons	I-IUPAC	B-MODIFIER
,	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
4b	O	O
)	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
4c	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
Phenyl	O	O
-	O	O
substituted	O	O
etoxadrol	O	O
analogues	O	O
were	O	O
compared	O	O
to	O	O
similarly	O	O
substituted	O	O
PCP	O	O
analogues	O	O
and	O	O
distinct	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
their	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
suggesting	O	O
that	O	O
the	O	O
aromatic	O	O
rings	O	O
in	O	O
these	O	O
two	O	O
drug	O	O
classes	O	O
interact	O	O
differently	O	O
with	O	O
the	O	O
PCP	O	O
binding	O	O
sites	O	O
.	O	O
Types	O	O
6	O	O
and	O	O
7	O	O
compounds	O	O
were	O	O
more	O	O
potent	O	O
than	O	O
the	O	O
corresponding	O	O
type	O	O
5	O	O
molecules	O	O
.	O	O
carinii	O	O
trophozoites	O	O
in	O	O
culture	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
10	O	O
microgram	O	O
/	O	O
mL	O	O
and	O	O
was	O	O
found	O	O
to	O	O
completely	O	O
suppress	O	O
growth	O	O
over	O	O
7	O	O
days	O	O
.	O	O
The	O	O
Trp	O	O
(	O	O
DNPS	O	O
)	O	O
-	O	O
containing	O	O
analogue	O	O
was	O	O
neurotoxic	O	O
.	O	O
To	O	O
develop	O	O
potent	O	O
H3	O	O
and	O	O
H4	O	O
receptor	O	O
antagonists	O	O
,	O	O
a	O	O
series	O	O
of	O	O
conformationally	O	O
restricted	O	O
analogues	O	O
of	O	O
histamine	O	O
with	O	O
a	O	O
chiral	B-MODIFIER	O
cis	B-PARTIUPAC	O
-	I-PARTIUPAC	O
or	O	O
trans	B-IUPAC	O
-	I-IUPAC	O
cyclopropane	I-IUPAC	O
structure	B-MODIFIER	O
were	O	O
designed	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
this	O	O
strategy	O	O
.	O	O
It	O	O
revealed	O	O
marked	O	O
anxiolytic	O	O
-	O	O
like	O	O
activity	O	O
in	O	O
the	O	O
Vogel	O	O
test	O	O
in	O	O
rats	O	O
,	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
the	O	O
reference	O	O
drug	O	O
diazepam	O	O
,	O	O
and	O	O
exhibited	O	O
antidepressant	O	O
-	O	O
like	O	O
activity	O	O
in	O	O
the	O	O
Porsolt	O	O
test	O	O
in	O	O
rats	O	O
.	O	O
The	O	O
protected	O	O
derivatives	O	O
were	O	O
deblocked	O	O
using	O	O
standard	O	O
conditions	O	O
to	O	O
afford	O	O
the	O	O
desired	O	O
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isothiazole	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
,	O	O
usually	O	O
as	O	O
crystalline	O	O
solids	O	O
.	O	O
sigma	O	O
receptor	O	O
affinities	O	O
ranged	O	O
from	O	O
1.34	O	O
nM	O	O
for	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
to	O	O
455	O	O
nM	O	O
for	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexylamine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
-	O	O
)	O	O
-	O	O
4	O	O
]	O	O
.	O	O
Compounds	O	O
with	O	O
substituents	O	O
(	O	O
F	O	O
,	O	O
CF3	O	O
,	O	O
Me	O	O
)	O	O
in	O	O
the	O	O
5	O	O
-	O	O
or	O	O
6	O	O
-	O	O
position	O	O
of	O	O
the	O	O
isobenzofuran	O	O
exert	O	O
increased	O	O
affinity	O	O
for	O	O
sigma	O	O
1	O	O
binding	O	O
sites	O	O
(	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
)	O	O
=	O	O
5-30	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
0.3-7	O	O
nM	O	O
)	O	O
,	O	O
thus	O	O
rendering	O	O
unselective	O	O
compounds	O	O
.	O	O
In	O	O
vitro	O	O
compounds	O	O
35	O	O
and	O	O
39	O	O
bound	O	O
to	O	O
[	O	O
3H	O	O
]	O	O
mepyramine	O	O
-	O	O
labeled	O	O
guinea	O	O
pig	O	O
cerebellar	O	O
membranes	O	O
with	O	O
a	O	O
pKi	O	O
of	O	O
6.1	O	O
and	O	O
5.9	O	O
,	O	O
respectively	O	O
.	O	O
Compound	O	O
17	O	O
was	O	O
unstable	O	O
in	O	O
tissue	O	O
culture	O	O
media	O	O
,	O	O
failed	O	O
to	O	O
achieve	O	O
nuclear	O	O
access	O	O
,	O	O
and	O	O
was	O	O
excluded	O	O
from	O	O
further	O	O
consideration	O	O
.	O	O
The	O	O
two	O	O
analogs	O	O
as	O	O
well	O	O
as	O	O
the	O	O
previously	O	O
reported	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
and	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
were	O	O
studied	O	O
as	O	O
growth	O	O
inhibitors	O	O
of	O	O
Escherichia	O	O
coli	O	O
9723	O	O
,	O	O
Leuconostoc	O	O
dextranicum	O	O
8086	O	O
,	O	O
and	O	O
Lactobacillus	O	O
plantarum	O	O
8014	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazafolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
and	O	O
its	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desamino	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
is	O	O
described	O	O
.	O	O
Antagonist	O	O
/	O	O
agonist	O	O
binding	O	O
ratios	O	O
were	O	O
not	O	O
obtained	O	O
for	O	O
transfected	O	O
m	O	O
(	O	O
3	O	O
)	O	O
-	O	O
receptors	O	O
,	O	O
since	O	O
significant	O	O
oxotremorine	O	O
-	O	O
M	O	O
binding	O	O
could	O	O
not	O	O
be	O	O
detected	O	O
.	O	O
Due	O	O
to	O	O
the	O	O
antiviral	O	O
activity	O	O
of	O	O
certain	O	O
5	O	O
-	O	O
substituted	O	O
imidazole	O	O
nucleosides	O	O
related	O	O
to	O	O
ribavirin	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
having	O	O
beta	B-IUPAC	O
-	I-IUPAC	O
D	I-IUPAC	O
-	I-IUPAC	O
ribofuranosyl	I-IUPAC	O
,	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
deoxy	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
beta	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
and	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
alpha	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
D	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
ribofuranosyl	I-PARTIUPAC	I-IUPAC
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
moieties	B-MODIFIER	B-MODIFIER
have	O	O
been	O	O
prepared	O	O
and	O	O
tested	O	O
as	O	O
antiviral	O	O
agents	O	O
.	O	O
All	O	O
compounds	O	O
prepared	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
leukemia	O	O
L1210	O	O
cell	O	O
proliferation	O	O
.	O	O
Also	O	O
included	O	O
in	O	O
the	O	O
study	O	O
were	O	O
3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
oxo	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3H	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
naphtho	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
2,1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
b	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
pyran	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
acetic	I-PARTIUPAC	I-IUPAC
,	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
oxo	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2H	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
naphtho	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
1,2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
b	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
pyran	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
acetic	I-PARTIUPAC	I-IUPAC
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthylacetic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
.	O	O
The	O	O
cytotoxicity	O	O
of	O	O
this	O	O
series	O	O
of	O	O
water	O	O
-	O	O
soluble	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylazopyridine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
has	O	O
been	O	O
determined	O	O
in	O	O
A2780	O	O
human	O	O
ovarian	O	O
carcinoma	O	O
and	O	O
A2780cisR	O	O
,	O	O
the	O	O
corresponding	O	O
cisplatin	O	O
-	O	O
resistant	O	O
cell	O	O
line	O	O
.	O	O
It	O	O
is	O	O
expected	O	O
that	O	O
compound	O	O
55	O	O
may	O	O
be	O	O
used	O	O
as	O	O
a	O	O
potent	O	O
drug	O	O
with	O	O
few	O	O
side	O	O
effects	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
psychosis	O	O
.	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
receptor	O	O
binding	O	O
affinity	O	O
was	O	O
not	O	O
only	O	O
dependent	O	O
on	O	O
the	O	O
number	O	O
of	O	O
RGD	O	O
moieties	O	O
but	O	O
also	O	O
on	O	O
the	O	O
spatial	O	O
alignments	O	O
of	O	O
the	O	O
pendant	O	O
peptides	O	O
.	O	O
4beta	B-IUPAC	O
,	I-IUPAC	O
19	I-IUPAC	O
-	I-IUPAC	O
Diol	I-IUPAC	O
27	O	O
,	O	O
previously	O	O
synthesized	O	O
,	O	O
was	O	O
identified	O	O
as	O	O
an	O	O
extremely	O	O
powerful	O	O
competitive	O	O
inhibitor	O	O
of	O	O
aromatase	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
3.4	O	O
nM	O	O
)	O	O
.	O	O
Additional	O	O
bioassay	O	O
data	O	O
for	O	O
these	O	O
compounds	O	O
are	O	O
also	O	O
reported	O	O
.	O	O
Pyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
bearing	O	O
bulky	O	O
,	O	O
weakly	O	O
basic	O	O
solubilizing	O	O
side	O	O
chains	O	O
linked	O	O
to	O	O
the	O	O
6	O	O
-	O	O
position	O	O
through	O	O
a	O	O
secondary	O	O
amine	O	O
generally	O	O
retained	O	O
potency	O	O
both	O	O
against	O	O
the	O	O
isolated	O	O
enzyme	O	O
and	O	O
for	O	O
inhibition	O	O
of	O	O
autophosphorylation	O	O
of	O	O
EGFR	O	O
in	O	O
intact	O	O
A431	O	O
cells	O	O
.	O	O
Two	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxythiophene	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethylbenzyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
,	O	O
3d	O	O
(	O	O
49%	O	O
)	O	O
and	O	O
3f	O	O
(	O	O
63%	O	O
)	O	O
,	O	O
had	O	O
substantial	O	O
AE	O	O
activity	O	O
.	O	O
These	O	O
results	O	O
add	O	O
to	O	O
our	O	O
earlier	O	O
study	O	O
where	O	O
we	O	O
restrained	O	O
1	O	O
using	O	O
simple	O	O
monocyclic	O	O
heterocycles	O	O
.	O	O
A	O	O
series	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
was	O	O
evaluated	O	O
for	O	O
anticonvulsant	O	O
activity	O	O
.	O	O
All	O	O
of	O	O
these	O	O
derivatives	O	O
retain	O	O
substantial	O	O
affinity	O	O
for	O	O
the	O	O
mu	O	O
opioid	O	O
receptor	O	O
.	O	O
The	O	O
ring	B-MODIFIER	O
-	I-MODIFIER	O
saturated	I-MODIFIER	O
analogue	I-MODIFIER	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
morpholino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
7'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
9'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrodibenzothiophene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
chromen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
,	O	O
36	O	O
,	O	O
retained	O	O
potent	O	O
activity	O	O
(	O	O
IC50	O	O
vs	O	O
DNA	O	O
-	O	O
PK	O	O
=	O	O
23	O	O
nM	O	O
)	O	O
.	O	O
DPEAP	O	O
(	O	O
2	O	O
)	O	O
and	O	O
related	O	O
compounds	O	O
provide	O	O
new	O	O
leads	O	O
for	O	O
the	O	O
development	O	O
of	O	O
antagonists	O	O
for	O	O
the	O	O
human	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
.	O	O
In	O	O
the	O	O
binding	O	O
assay	O	O
,	O	O
the	O	O
relative	O	O
order	O	O
of	O	O
potencies	O	O
for	O	O
the	O	O
analogues	O	O
in	O	O
the	O	O
5alpha	O	B-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
5beta	O	O
-	O	O
series	O	O
is	O	O
identical	O	O
.	O	O
Furthermore	O	O
,	O	O
it	O	O
antagonized	O	O
in	O	O
vivo	O	O
seizures	O	O
induced	O	O
by	O	O
icv	O	O
administration	O	O
of	O	O
AMPA	O	O
or	O	O
kainate	O	O
(	O	O
KA	O	O
)	O	O
.	O	O
Diazotization	O	O
of	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzazocine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
followed	O	O
by	O	O
the	O	O
reaction	O	O
with	O	O
CH3SNa	O	O
afforded	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzazocine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
.	O	O
Spontaneous	O	O
elimination	O	O
of	O	O
acrolein	O	O
from	O	O
3a	O	O
would	O	O
then	O	O
generate	O	O
the	O	O
free	O	O
nucleotide	O	O
,	O	O
FdUMP	O	O
.	O	O
Finally	O	O
,	O	O
there	O	O
was	O	O
no	O	O
correlation	O	O
between	O	O
the	O	O
SAR	O	O
for	O	O
the	O	O
human	O	O
MDR1	O	O
Pgp	O	O
inhibition	O	O
and	O	O
the	O	O
SAR	O	O
for	O	O
Saccharomyces	O	O
cerevisiae	O	O
antifungal	O	O
activity	O	O
,	O	O
which	O	O
is	O	O
mediated	O	O
by	O	O
an	O	O
inositol	O	O
phosphoceramide	O	O
synthase	O	O
activity	O	O
.	O	O
When	O	O
compounds	O	O
were	O	O
intraduodenally	O	O
administered	O	O
to	O	O
the	O	O
guinea	O	O
pig	O	O
,	O	O
1	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2'	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
ethoxyethyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
,	O	I-IUPAC
1	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3'	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methoxypropyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
,	O	I-IUPAC
1	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3'	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
butenyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylxanthines	I-IUPAC	I-IUPAC
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylxanthine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
denbufylline	O	B-IUPAC
(	O	I-IUPAC
1,3	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
xanthine	I-IUPAC	I-IUPAC
)	O	O
effectively	O	O
inhibited	O	O
the	O	O
acetylcholine	O	O
-	O	O
induced	O	O
bronchospasm	O	O
without	O	O
heart	O	O
stimulation	O	O
or	O	O
central	O	O
nervous	O	O
system	O	O
-	O	O
stimulation	O	O
at	O	O
the	O	O
effective	O	O
dosage	O	O
range	O	O
.	O	O
Excellent	O	O
in	O	O
vivo	O	O
activity	O	O
in	O	O
the	O	O
trypanosomal	O	O
STIB900	O	O
mouse	O	O
model	O	O
was	O	O
found	O	O
for	O	O
five	O	O
of	O	O
the	O	O
diamidines	O	O
on	O	O
ip	O	O
dosage	O	O
;	O	O
these	O	O
compounds	O	O
gave	O	O
4/4	O	O
cures	O	O
in	O	O
this	O	O
model	O	O
.	O	O
Compounds	O	O
14	O	O
,	O	O
15	O	O
,	O	O
18	O	O
,	O	O
19	O	O
,	O	O
and	O	O
21	O	O
,	O	O
mostly	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenylpiperazine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
can	O	O
be	O	O
classified	O	O
as	O	O
mixed	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
/	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
2A	O	O
)	O	O
/	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
ligands	O	O
.	O	O
The	O	O
remaining	O	O
target	O	O
compounds	O	O
were	O	O
produced	O	O
by	O	O
alkylation	O	O
of	O	O
lidocaine	O	O
or	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phthalimidoaceto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
xylidide	I-IUPAC	I-IUPAC
with	O	O
the	O	O
appropriate	O	O
halide	O	O
and	O	O
sodium	O	O
hydride	O	O
,	O	O
followed	O	O
by	O	O
hydrazinolysis	O	O
where	O	O
necessary	O	O
.	O	O
All	O	O
had	O	O
retained	O	O
or	O	O
improved	O	O
activity	O	O
against	O	O
both	O	O
the	O	O
L1210	O	O
:	O	O
R7A	O	O
and	O	O
L1210	O	O
:	O	O
1565	O	O
cell	O	O
lines	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylhydroxypropynyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
Ado	O	O
(	O	O
9e	O	O
,	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
(	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
)	O	O
=	O	O
0.73	O	O
microM	O	O
)	O	O
showed	O	O
a	O	O
significantly	O	O
increase	O	O
of	O	O
potency	O	O
at	O	O
the	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
subtype	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
the	O	O
unsubstituted	O	O
adenosine	O	O
derivatives	O	O
,	O	O
although	O	O
it	O	O
resulted	O	O
in	O	O
being	O	O
less	O	O
potent	O	O
than	O	O
(	O	O
S	O	O
)	O	O
-	O	O
PHPNECA	O	O
(	O	O
1e	O	O
,	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
(	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
)	O	O
=	O	O
0.22	O	O
microM	O	O
)	O	O
.	O	O
Other	O	O
linkers	O	O
between	O	O
the	O	O
naphthalene	O	O
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thiazolidinedione	I-IUPAC	I-IUPAC
rings	B-MODIFIER	B-MODIFIER
,	O	O
such	O	O
as	O	O
thio	O	O
,	O	O
methylene	O	O
,	O	O
oxy	O	O
,	O	O
and	O	O
sulfinyl	O	O
led	O	O
to	O	O
decreased	O	O
antihyperglycemic	O	O
activity	O	O
.	O	O
Heteroarotinoids	O	O
8	O	O
and	O	O
12-17	O	O
had	O	O
ID50	O	O
values	O	O
of	O	O
35	O	O
nmol	O	O
or	O	O
greater	O	O
.	O	O
A	O	O
number	O	O
of	O	O
nitrogen	O	O
analogues	O	O
of	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanine	I-IUPAC	I-IUPAC
[	O	O
acylovir	O	O
,	O	O
Zovirax	O	O
]	O	O
containing	O	O
amine	O	O
functions	O	O
in	O	O
the	O	O
side	O	O
chain	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
antiviral	O	O
activity	O	O
.	O	O
4,5	O	B-IUPAC
-	O	I-IUPAC
Diphenyl	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
oxazolenonanoic	O	I-IUPAC
acid	O	I-IUPAC
(	O	O
2	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
phenoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
acetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
were	O	O
previously	O	O
identified	O	O
as	O	O
nonprostanoid	O	O
prostacyclin	O	O
(	O	O
PGI2	O	O
)	O	O
mimetics	O	O
that	O	O
inhibit	O	O
ADP	O	O
-	O	O
induced	O	O
aggregation	O	O
of	O	O
human	O	O
platelets	O	O
in	O	O
vitro	O	O
.	O	O
Selective	O	O
condensation	O	O
of	O	O
5	O	O
with	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
substituted	B-MODIFIER	I-IUPAC
-	O	I-IUPAC
phenyl	B-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
gave	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arylpiperazinylethylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
6a	O	O
-	O	O
c	O	O
,	O	O
which	O	O
were	O	O
investigated	O	O
in	O	O
binding	O	O
studies	O	O
toward	O	O
the	O	O
three	O	O
alpha1	O	O
-	O	O
adrenergic	O	O
and	O	O
5	O	O
-	O	O
HT1A	O	O
-	O	O
serotonergic	O	O
receptor	O	O
subtypes	O	O
.	O	O
The	O	O
major	O	O
product	O	O
of	O	O
conjugation	O	O
had	O	O
the	O	O
opposite	O	O
stereochemistry	O	O
at	O	O
the	O	O
benzylic	O	O
carbon	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
reaction	O	O
proceeded	O	O
primarily	O	O
with	O	O
inversion	O	O
of	O	O
configuration	O	O
.	O	O
Phototoxic	O	O
liability	O	O
precluded	O	O
clinical	O	O
evaluation	O	O
of	O	O
a	O	O
member	O	O
of	O	O
the	O	O
series	O	O
.	O	O
Crystal	O	O
structure	O	O
determinations	O	O
have	O	O
been	O	O
carried	O	O
out	O	O
for	O	O
the	O	O
following	O	O
seven	O	O
thyrotropin	O	O
releasing	O	O
hormone	O	O
analogues	O	O
:	O	O
I	O	O
,	O	O
(	B-IUPAC	B-IUPAC
3R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxothiomorpholin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylcarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
histidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
;	O	O
II	O	O
,	O	O
(	B-IUPAC	B-IUPAC
3R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxothiomorpholin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylcarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
histid	I-IUPAC	I-IUPAC
inyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
;	O	O
III	O	O
,	O	O
(	B-IUPAC	B-IUPAC
4R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxothiazolidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylcarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
histidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
prol	I-IUPAC	I-IUPAC
ine	I-IUPAC	O
amide	I-IUPAC	O
;	O	O
IV	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethylorotyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
histidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
;	O	O
V	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylorotyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
histidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
;	O	O
VI	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromoorotyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
histidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
;	O	O
and	O	O
VII	O	O
,	O	O
Phe2	O	O
-	O	O
TRH	O	O
.	O	O
The	O	O
results	O	O
obtained	O	O
with	O	O
different	O	O
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfamoylbenzoic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
supported	O	O
the	O	O
earlier	O	O
concept	O	O
regarding	O	O
the	O	O
steric	O	O
influence	O	O
of	O	O
the	O	O
4	O	O
-	O	O
substituent	O	O
on	O	O
the	O	O
diuretic	O	O
potency	O	O
of	O	O
sulfamoylbenzoic	O	O
acid	O	O
diuretics	O	O
.	O	O
Marked	O	O
inhibition	O	O
of	O	O
tetrabenazine	O	O
-	O	O
induced	O	O
ptosis	O	O
is	O	O
a	O	O
property	O	O
of	O	O
most	O	O
antidepressants	O	O
,	O	O
and	O	O
significant	O	O
antitetrabenazine	O	O
activity	O	O
is	O	O
observed	O	O
for	O	O
several	O	O
of	O	O
these	O	O
compounds	O	O
.	O	O
A	O	O
series	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
naphthalenylsulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolidinediones	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
antihyperglycemic	O	O
activity	O	O
in	O	O
an	O	O
insulin	O	O
-	O	O
resistant	O	O
,	O	O
genetically	O	O
diabetic	O	O
db	O	O
/	O	O
db	O	O
mouse	O	O
model	O	O
of	O	O
non	O	O
-	O	O
insulin	O	O
-	O	O
dependent	O	O
diabetes	O	O
mellitus	O	O
(	O	O
NIDDM	O	O
)	O	O
.	O	O
Location	O	O
of	O	O
the	O	O
fluorine	O	O
atom	O	O
at	O	O
the	O	O
C	O	O
-	O	O
4	O	O
position	O	O
of	O	O
the	O	O
piperidine	O	O
ring	O	O
was	O	O
the	O	O
most	O	O
favorable	O	O
,	O	O
and	O	O
among	O	O
the	O	O
various	O	O
substituents	O	O
tested	O	O
,	O	O
the	O	O
ability	O	O
of	O	O
the	O	O
fluorine	O	O
was	O	O
unique	O	O
in	O	O
improving	O	O
the	O	O
oral	O	O
activity	O	O
of	O	O
this	O	O
family	O	O
of	O	O
ligands	O	O
.	O	O
N	B-IUPAC	O
-	I-IUPAC	O
Acetyl	I-IUPAC	O
derivatives	B-MODIFIER	O
showed	O	O
irreversible	O	O
inactivation	O	O
vis	O	O
-	O	O
a	O	O
-	O	O
vis	O	O
subtilisin	O	O
,	O	O
while	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
specific	O	O
toward	O	O
chymotrypsin	O	O
.	O	O
The	O	O
9	B-IUPAC	O
-	I-IUPAC	O
aza	I-IUPAC	O
analogue	B-MODIFIER	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
demethoxydaunomycin	I-IUPAC	I-IUPAC
has	O	O
been	O	O
synthesized	O	O
from	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzaldehyde	I-IUPAC	I-IUPAC
.	O	O
gamma	O	O
-	O	O
CyanoMTX	O	O
may	O	O
be	O	O
viewed	O	O
as	O	O
a	O	O
congener	O	O
of	O	O
the	O	O
nonpolyglutamated	O	O
MTX	O	O
analogue	O	O
gamma	O	O
-	O	O
fluoroMTX	O	O
.	O	O
Incorporation	O	O
of	O	O
a	O	O
fluorine	O	O
atom	O	O
in	O	O
the	O	O
beta	O	O
-	O	O
position	O	O
to	O	O
the	O	O
amino	O	O
function	O	O
in	O	O
the	O	O
side	O	O
chain	O	O
led	O	O
to	O	O
analogues	O	O
that	O	O
exhibited	O	O
,	O	O
in	O	O
general	O	O
,	O	O
enhanced	O	O
and	O	O
long	O	O
-	O	O
lasting	O	O
5	O	O
-	O	O
HT1A	O	O
agonist	O	O
activity	O	O
in	O	O
rats	O	O
after	O	O
oral	O	O
administration	O	O
.	O	O
Pirenzepine	O	O
displayed	O	O
a	O	O
higher	O	O
potency	O	O
than	O	O
II	O	O
for	O	O
inhibition	O	O
of	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
l	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinuclidinyl	I-IUPAC	I-IUPAC
benzilate	I-IUPAC	I-IUPAC
(	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
l	O	O
-	O	O
QNB	O	O
)	O	O
binding	O	O
to	O	O
rat	O	O
brain	O	O
sections	O	O
.	O	O
However	O	O
,	O	O
there	O	O
was	O	O
only	O	O
modest	O	O
separation	O	O
between	O	O
activity	O	O
against	O	O
HCMV	O	O
and	O	O
cytotoxicity	O	O
and	O	O
there	O	O
was	O	O
virtually	O	O
no	O	O
selectivity	O	O
for	O	O
activity	O	O
against	O	O
HSV	O	O
-	O	O
1	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
prepared	O	O
by	O	O
two	O	O
methods	O	O
:	O	O
(	O	O
1	O	O
)	O	O
direct	O	O
alkylation	O	O
of	O	O
adenosine	O	O
with	O	O
an	O	O
appropriately	O	O
substituted	O	B-MODIFIER
benzyl	O	B-IUPAC
bromide	O	I-IUPAC
to	O	O
give	O	O
the	O	O
N1	O	O
-	O	O
substituted	O	O
derivative	O	O
which	O	O
was	O	O
then	O	O
rearranged	O	O
in	O	O
base	O	O
to	O	O
give	O	O
the	O	O
N6	O	O
-	O	O
substituted	O	O
compound	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
by	O	O
nucleophilic	O	O
displacement	O	O
of	O	O
chlorine	O	O
in	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
ribonucleoside	B-MODIFIER	I-IUPAC
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopurine	I-IUPAC	I-IUPAC
ribonucleoside	B-MODIFIER	I-IUPAC
,	O	O
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopurine	I-IUPAC	I-IUPAC
with	O	O
an	O	O
amine	O	O
.	O	O
Compounds	O	O
9-13	O	O
and	O	O
15	O	O
were	O	O
shown	O	O
to	O	O
be	O	O
essentially	O	O
inactive	O	O
against	O	O
isoniazide	O	O
-	O	O
induced	O	O
convulsions	O	O
in	O	O
mice	O	O
after	O	O
subcutaneous	O	O
administration	O	O
.	O	O
More	O	O
convenient	O	O
one	O	O
-	O	O
pot	O	O
alkylation	O	O
-	O	O
elimination	O	O
of	O	O
adenine	O	O
(	O	O
18	O	O
)	O	O
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
(	O	O
30	O	O
)	O	O
with	O	O
24	O	O
+	O	O
25	O	O
afforded	O	O
(	B-PARTIUPAC	B-PARTIUPAC
Z	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenecyclopropane	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
26	O	O
+	O	O
27	O	O
and	O	O
31	O	O
+	O	O
32	O	O
.	O	O
Of	O	O
the	O	O
newly	O	O
synthesized	O	O
compounds	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanamido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
exhibited	O	O
the	O	O
most	O	O
potent	O	O
anti	O	O
-	O	O
HSV	O	O
-	O	O
1	O	O
activity	O	O
,	O	O
which	O	O
was	O	O
equipotent	O	O
to	O	O
acyclovir	O	O
and	O	O
superior	O	O
to	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
EDU	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
also	O	O
found	O	O
to	O	O
bind	O	O
to	O	O
site	O	O
II	O	O
of	O	O
human	O	O
serum	O	O
albumin	O	O
(	O	O
HSA	O	O
)	O	O
.	O	O
Synadenol	O	O
(	O	O
14	O	O
)	O	O
and	O	O
the	O	O
E	O	O
-	O	O
isomer	O	O
(	O	O
16	O	O
)	O	O
were	O	O
substrates	O	O
of	O	O
moderate	O	O
efficiency	O	O
for	O	O
adenosine	O	O
deaminase	O	O
from	O	O
calf	O	O
intestine	O	O
.	O	O
However	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
also	O	O
showed	O	O
moderate	O	O
affinity	O	O
for	O	O
sigma	O	O
receptors	O	O
,	O	O
with	O	O
a	O	O
Ki	O	O
of	O	O
594	O	O
+	O	O
/	O	O
-	O	O
3	O	O
nM	O	O
[	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
]	O	O
.	O	O
On	O	O
the	O	O
whole	O	O
,	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
(	O	O
-	O	O
)	O	O
insulin	O	O
represents	O	O
a	O	O
prototype	O	O
version	O	O
of	O	O
a	O	O
water	O	O
-	O	O
soluble	O	O
,	O	O
long	O	O
-	O	O
acting	O	O
preparation	O	O
of	O	O
insulin	O	O
.	O	O
This	O	O
also	O	O
implies	O	O
,	O	O
therefore	O	O
,	O	O
that	O	O
the	O	O
hallucinogenic	O	O
phenethylamines	O	O
cannot	O	O
be	O	O
directly	O	O
superimposed	O	O
on	O	O
LSD	O	O
in	O	O
a	O	O
common	O	O
binding	O	O
orientation	O	O
for	O	O
these	O	O
two	O	O
chemical	O	O
classes	O	O
,	O	O
contrary	O	O
to	O	O
previous	O	O
hypotheses	O	O
.	O	O
Phosphorylation	O	O
of	O	O
unprotected	O	O
4	O	O
with	O	O
POCl3	O	O
and	O	O
subsequent	O	O
debenzylation	O	O
of	O	O
the	O	O
intermediate	O	O
17	O	O
gave	O	O
pyrazofurin	B-IUPAC	B-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphate	I-IUPAC	I-IUPAC
(	O	O
18	O	O
)	O	O
,	O	O
which	O	O
provided	O	O
the	O	O
first	O	O
chemical	O	O
synthesis	O	O
of	O	O
18	O	O
.	O	O
The	O	O
(	B-IUPAC	B-IUPAC
glycolato	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
platinum	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
were	O	O
highly	O	O
cytotoxic	O	O
toward	O	O
four	O	O
human	O	O
stomach	O	O
cancer	O	O
cell	O	O
lines	O	O
,	O	O
SNU	O	O
-	O	O
1	O	O
,	O	O
SNU	O	O
-	O	O
5	O	O
,	O	O
SNU	O	O
-	O	O
16	O	O
,	O	O
and	O	O
NCI	O	O
-	O	O
N87	O	O
,	O	O
and	O	O
among	O	O
them	O	O
,	O	O
complexes	O	O
3d	O	O
-	O	O
g	O	O
were	O	O
even	O	O
more	O	O
cytotoxic	O	O
than	O	O
cisplatin	O	O
.	O	O
Functionally	O	O
,	O	O
the	O	O
stereoisomers	O	O
displayed	O	O
a	O	O
similar	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
-	O	O
selectivity	O	O
profile	O	O
,	O	O
that	O	O
is	O	O
alpha	O	O
(	O	O
1D	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
alpha	O	O
(	O	O
1B	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
alpha	O	O
(	O	O
1A	O	O
)	O	O
,	O	O
which	O	O
is	O	O
different	O	O
from	O	O
that	O	O
exhibited	O	O
by	O	O
the	O	O
reference	O	O
compound	O	O
1	O	O
.	O	O
The	O	O
lead	O	O
compound	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluoylethynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
effectively	O	O
inhibited	O	O
thymidylate	O	O
synthetase	O	O
.	O	O
A	O	O
series	O	O
of	O	O
esters	O	O
of	O	O
6beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxynortropane	I-IUPAC	I-IUPAC
and	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
6beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tropanol	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
screened	O	O
versus	O	O
binding	O	O
of	O	O
an	O	O
antagonist	O	O
(	O	O
quinuclidinyl	B-IUPAC	O
benzilate	I-IUPAC	O
)	O	O
and	O	O
an	O	O
agonist	O	O
(	O	O
oxotremorine	O	O
-	O	O
M	O	O
)	O	O
at	O	O
sites	O	O
on	O	O
human	O	O
m	O	O
(	O	O
1	O	O
)	O	O
-	O	O
,	O	O
m	O	O
(	O	O
2	O	O
)	O	O
-	O	O
,	O	O
m	O	O
(	O	O
3	O	O
)	O	O
-	O	O
,	O	O
and	O	O
m	O	O
(	O	O
4	O	O
)	O	O
-	O	O
muscarinic	O	O
receptors	O	O
in	O	O
transfected	O	O
cell	O	O
membranes	O	O
and	O	O
on	O	O
native	O	O
M	O	O
(	O	O
1	O	O
)	O	O
-	O	O
muscarinic	O	O
receptors	O	O
in	O	O
rat	O	O
brain	O	O
membranes	O	O
and	O	O
native	O	O
M	O	O
(	O	O
2	O	O
)	O	O
-	O	O
muscarinic	O	O
receptors	O	O
in	O	O
rat	O	O
heart	O	O
membranes	O	O
.	O	O
The	O	O
various	O	O
C11	O	O
-	O	O
substituents	O	O
were	O	O
introduced	O	O
using	O	O
efficient	O	O
nickel	O	O
-	O	O
and	O	O
palladium	O	O
-	O	O
catalyzed	O	O
reactions	O	O
of	O	O
the	O	O
corresponding	O	O
triflate	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
aporphine	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
.	O	O
Among	O	O
these	O	O
tyrosine	O	O
analogues	O	O
were	O	O
the	O	O
bicyclic	O	O
structures	O	O
1,2,3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
HO	O	O
-	O	O
Tic	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxytetralin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
Hat	O	O
)	O	O
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyindan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
Hai	O	O
)	O	O
in	O	O
which	O	O
rotations	O	O
about	O	O
the	O	O
C	O	O
alpha	O	O
-	O	O
C	O	O
beta	O	O
and	O	O
C	O	O
beta	O	O
-	O	O
C	O	O
gamma	O	O
bonds	O	O
are	O	O
restricted	O	O
due	O	O
to	O	O
cyclization	O	O
of	O	O
the	O	O
side	O	O
chain	O	O
to	O	O
the	O	O
backbone	O	O
.	O	O
Incubation	O	O
of	O	O
1	O	O
and	O	O
glutathione	O	O
under	O	O
the	O	O
same	O	O
experimental	O	O
conditions	O	O
yields	O	O
the	O	O
(	B-MODIFIER	O
2R	I-MODIFIER	O
,	I-MODIFIER	O
4R	I-MODIFIER	O
)	I-MODIFIER	O
-	I-MODIFIER	O
and	O	O
(	B-MODIFIER	B-IUPAC
2S	I-MODIFIER	I-IUPAC
,	I-MODIFIER	I-IUPAC
4R	I-MODIFIER	I-IUPAC
)	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
epimers	I-MODIFIER	I-IUPAC
of	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carboxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
delta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolidinepentanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
Among	O	O
the	O	O
resolved	O	O
analogs	O	O
tested	O	O
,	O	O
the	O	O
activity	O	O
was	O	O
found	O	O
to	O	O
reside	O	O
exclusively	O	O
in	O	O
the	O	O
(	O	O
3aS	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
enantiomers	O	O
.	O	O
A	O	O
structural	O	O
isomer	O	O
of	O	O
2	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazaphosphorin	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
and	O	O
cognate	O	O
systems	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodiazaphosphorin	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodioxaphosphorin	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
were	O	O
also	O	O
prepared	O	O
for	O	O
comparative	O	O
purposes	O	O
.	O	O
Both	O	O
12a	O	O
and	O	O
its	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
analogue	B-MODIFIER	O
12b	O	O
were	O	O
converted	O	O
to	O	O
versatile	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
intermediates	B-MODIFIER	O
13a	O	O
and	O	O
13b	O	O
from	O	O
which	O	O
important	O	O
antifolates	O	O
may	O	O
be	O	O
readily	O	O
derived	O	O
.	O	O
These	O	O
compounds	O	O
showed	O	O
significant	O	O
inhibitory	O	O
action	O	O
against	O	O
isonicotinic	O	O
acid	O	O
hydrazide	O	O
and	O	O
streptomycin	O	O
-	O	O
resistant	O	O
strains	O	O
of	O	O
M	O	O
.	O	O
The	O	O
CoMFA	O	O
models	O	O
with	O	O
steric	O	O
and	O	O
electrostatic	O	O
fields	O	O
exhibited	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
cv	O	O
)	O	O
0.452-0.722	O	O
,	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
ncv	O	O
)	O	O
0.812-0.986	O	O
,	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
pred	O	O
)	O	O
0.597-0.870	O	O
,	O	O
whereas	O	O
CoMFA	O	O
ClogP	O	O
models	O	O
showed	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
cv	O	O
)	O	O
0.420-0.707	O	O
,	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
ncv	O	O
)	O	O
0.849-0.957	O	O
,	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
pred	O	O
)	O	O
0.600-0.870	O	O
.	O	O
MIH	O	O
possessed	O	O
a	O	O
maleimide	O	O
group	O	O
for	O	O
mAb	O	O
conjugation	O	O
and	O	O
a	O	O
butylstannyl	O	B-IUPAC
moiety	O	B-MODIFIER
for	O	O
high	O	O
-	O	O
yield	O	O
and	O	O
site	O	O
-	O	O
specific	O	O
radioiodination	O	O
,	O	O
and	O	O
the	O	O
two	O	O
functional	O	O
groups	O	O
were	O	O
linked	O	O
via	O	O
an	O	O
ester	O	O
bond	O	O
to	O	O
release	O	O
m	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodohippuric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
In	O	O
contrast	O	O
,	O	O
three	O	O
compounds	O	O
,	O	O
17c	O	O
,	O	O
24	O	O
,	O	O
and	O	O
26	O	O
,	O	O
displayed	O	O
moderate	O	O
to	O	O
high	O	O
affinity	O	O
for	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
cytisine	O	O
binding	O	O
sites	O	O
,	O	O
while	O	O
three	O	O
(	O	O
17b	O	O
,	O	O
18b	O	O
,	O	O
c	O	O
)	O	O
and	O	O
six	O	O
(	O	O
17a	O	O
,	O	O
d	O	O
,	O	O
e	O	O
and	O	O
18a	O	O
,	O	O
d	O	O
,	O	O
e	O	O
)	O	O
compounds	O	O
showed	O	O
weak	O	O
and	O	O
poor	O	O
affinity	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
these	O	O
same	O	O
sites	O	O
.	O	O
Further	O	O
derivatizations	O	O
provided	O	O
an	O	O
additional	O	O
group	O	O
of	O	O
pyrido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
.	O	O
Sulfonation	O	O
of	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylisoquinoline	I-IUPAC	I-IUPAC
,	O	O
followed	O	O
by	O	O
reaction	O	O
with	O	O
potassium	O	O
hydroxide	O	O
,	O	O
acetylation	O	O
,	O	O
and	O	O
oxidation	O	O
,	O	O
gave	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxaldehyde	I-IUPAC	I-IUPAC
(	O	O
40	O	O
)	O	O
.	O	O
The	O	O
analogue	O	O
[	O	O
CalphaMe	O	O
-	O	O
Leu27	O	O
,	O	O
DHis32	O	O
]	O	O
astressin	O	O
(	O	O
16	O	O
)	O	O
was	O	O
more	O	O
potent	O	O
(	O	O
although	O	O
not	O	O
statistically	O	O
in	O	O
all	O	O
cases	O	O
)	O	O
than	O	O
the	O	O
other	O	O
four	O	O
analogues	O	O
in	O	O
vitro	O	O
.	O	O
However	O	O
,	O	O
a	O	O
selective	O	O
inhibition	O	O
to	O	O
the	O	O
cancer	O	O
cells	O	O
was	O	O
observed	O	O
for	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
xylofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
2b	O	O
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
potent	O	O
inhibitor	O	O
of	O	O
HTB	O	O
-	O	O
81	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
:	O	O
0.73	O	O
microM	O	O
)	O	O
and	O	O
has	O	O
a	O	O
favorable	O	O
in	O	O
vitro	O	O
selectivity	O	O
index	O	O
(	O	O
28	O	O
)	O	O
.	O	O
In	O	O
general	O	O
,	O	O
3alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diphenylmethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tropane	I-IUPAC	I-IUPAC
(	O	O
benztropine	O	O
)	O	O
-	O	O
based	O	O
dopamine	O	O
uptake	O	O
inhibitors	O	O
do	O	O
not	O	O
demonstrate	O	O
cocaine	O	O
-	O	O
like	O	O
pharmacological	O	O
activity	O	O
in	O	O
models	O	O
of	O	O
psychostimulant	O	O
abuse	O	O
and	O	O
have	O	O
been	O	O
proposed	O	O
as	O	O
potential	O	O
medications	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
cocaine	O	O
addiction	O	O
.	O	O
Variable	O	O
-	O	O
temperature	O	O
proton	O	O
nuclear	O	O
magnetic	O	O
resonance	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpiperazino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cycloheptene	I-IUPAC	I-IUPAC
,	O	O
a	O	O
5,11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dicarbo	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
of	O	O
the	O	O
atypical	O	O
neuroleptic	O	O
agent	O	O
clozapine	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpiperazino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
,	O	O
exists	O	O
as	O	O
thermally	O	O
stable	O	O
configurational	O	O
isomers	O	O
.	O	O
In	O	O
monkeys	O	O
,	O	O
23	O	O
showed	O	O
no	O	O
morphine	O	O
-	O	O
like	O	O
physical	O	O
dependence	O	O
liability	O	O
,	O	O
cis	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinol	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
24	O	O
and	O	O
25	O	O
showed	O	O
no	O	O
binding	O	O
to	O	O
the	O	O
opiate	O	O
receptor	O	O
in	O	O
rat	O	O
brain	O	O
homogenates	O	O
.	O	O
Biodistribution	O	O
results	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
-	O	O
10	O	O
in	O	O
mice	O	O
indicate	O	O
that	O	O
compound	O	O
10	O	O
is	O	O
readily	O	O
metabolized	O	O
via	O	O
deiodination	O	O
in	O	O
vivo	O	O
,	O	O
possibly	O	O
by	O	O
serving	O	O
as	O	O
a	O	O
substrate	O	O
for	O	O
the	O	O
enzyme	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
adenosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
hydrolase	O	I-IUPAC
.	O	O
A	O	O
series	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylisoquinolone	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
NK1	O	O
(	O	O
substance	O	O
P	O	O
)	O	O
antagonist	O	O
activity	O	O
.	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethynylbenzyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
28	O	O
)	O	O
,	O	O
with	O	O
an	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
23	O	O
nM	O	O
and	O	O
an	O	O
SI	O	O
of	O	O
28	O	O
in	O	O
the	O	O
Pc	O	O
DHFR	O	O
assay	O	O
,	O	O
had	O	O
about	O	O
the	O	O
same	O	O
potency	O	O
as	O	O
PTX	O	O
and	O	O
was	O	O
520	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
TMP	O	O
.	O	O
Compound	O	O
10	O	O
is	O	O
inactive	O	O
in	O	O
both	O	O
test	O	O
systems	O	O
.	O	O
The	O	O
predicted	O	O
binding	O	O
model	O	O
for	O	O
ILV	O	O
is	O	O
the	O	O
same	O	O
as	O	O
that	O	O
obtained	O	O
in	O	O
a	O	O
previous	O	O
docking	O	O
study	O	O
using	O	O
a	O	O
Monte	O	O
Carlo	O	O
method	O	O
and	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
for	O	O
this	O	O
class	O	O
of	O	O
ligands	O	O
.	O	O
A	O	O
number	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
heteroaromatic	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	B-MODIFIER
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridines	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
from	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
using	O	O
tetraorganotin	O	O
reagents	O	O
and	O	O
palladium	O	O
complexes	O	O
as	O	O
catalyst	O	O
.	O	O
The	O	O
antimicrobial	O	O
and	O	O
cytotoxic	O	O
properties	O	O
of	O	O
a	O	O
series	O	O
of	O	O
9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenanthrenes	I-IUPAC	I-IUPAC
structurally	O	O
related	O	O
to	O	O
juncusol	O	O
(	O	O
1a	O	O
)	O	O
,	O	O
a	O	O
postulated	O	O
phytoalexin	O	O
with	O	O
confirmed	O	O
cytotoxic	O	O
properties	O	O
,	O	O
are	O	O
detailed	O	O
.	O	O
We	O	O
have	O	O
developed	O	O
a	O	O
generally	O	O
applicable	O	O
,	O	O
convenient	O	O
stepwise	O	O
solid	O	O
-	O	O
phase	O	O
synthetic	O	O
protocol	O	O
for	O	O
octreotide	O	O
(	O	O
D	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
D	O	O
-	O	O
Trp	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Cys	O	O
-	O	O
threoninol	O	O
)	O	O
.	O	O
The	O	O
ultimate	O	O
activity	O	O
kinetic	O	O
assay	O	O
(	O	O
Daniels	O	O
,	O	O
S	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
benzimidazoles	O	O
showed	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
AII	O	O
receptor	O	O
(	O	O
IC50	O	O
value	O	O
,	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
-	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
M	O	O
)	O	O
and	O	O
inhibited	O	O
the	O	O
AII	O	O
-	O	O
induced	O	O
pressor	O	O
response	O	O
at	O	O
1	O	O
or	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
po	O	O
,	O	O
and	O	O
the	O	O
effects	O	O
were	O	O
more	O	O
potent	O	O
than	O	O
those	O	O
of	O	O
CV	O	O
-	O	O
11194	O	O
and	O	O
DuP	O	O
753	O	O
.	O	O
Important	O	O
hydrogen	O	O
-	O	O
bonding	O	O
and	O	O
hydrophobic	O	O
interactions	O	O
with	O	O
the	O	O
protein	O	O
have	O	O
been	O	O
identified	O	O
for	O	O
this	O	O
inhibitor	O	O
.	O	O
In	O	O
addition	O	O
to	O	O
their	O	O
5	O	O
alpha	O	O
-	O	O
reductase	O	O
activities	O	O
,	O	O
17	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylformamides	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
were	O	O
also	O	O
studied	O	O
for	O	O
their	O	O
inhibitory	O	O
activities	O	O
on	O	O
dihydrotestosterone	O	O
(	O	O
DHT	O	O
)	O	O
-	O	O
stimulated	O	O
proliferation	O	O
of	O	O
androgen	O	O
-	O	O
sensitive	O	O
Shionogi	O	O
mouse	O	O
mammary	O	O
carcinoma	O	O
cells	O	O
(	O	O
clone	O	O
SEM	O	O
-	O	O
107	O	O
)	O	O
.	O	O
Compound	O	O
4d	O	O
had	O	O
affinities	O	O
of	O	O
12-33	O	O
nM	O	O
at	O	O
all	O	O
of	O	O
the	O	O
muscarinic	O	O
sites	O	O
,	O	O
with	O	O
4b	O	O
,	O	O
e	O	O
having	O	O
much	O	O
lower	O	O
affinity	O	O
.	O	O
A	O	O
conjugate	O	O
of	O	O
Boc	O	B-IUPAC
-	O	I-IUPAC
gamma	O	I-IUPAC
-	O	I-IUPAC
aminobutyric	O	I-IUPAC
acid	O	I-IUPAC
was	O	O
also	O	O
prepared	O	O
but	O	O
was	O	O
nonselective	O	O
.	O	O
N	O	B-IUPAC
-	O	I-IUPAC
Alkyl	O	I-IUPAC
derivatives	O	B-MODIFIER
of	O	O
dexoxadrol	O	O
were	O	O
found	O	O
to	O	O
be	O	O
inactive	O	O
,	O	O
as	O	O
were	O	O
those	O	O
analogues	O	O
where	O	O
the	O	O
dioxolane	O	O
ring	O	O
was	O	O
modified	O	O
.	O	O
The	O	O
combined	O	O
results	O	O
from	O	O
these	O	O
systematic	O	O
studies	O	O
allowed	O	O
for	O	O
an	O	O
analysis	O	O
of	O	O
structural	O	O
features	O	O
in	O	O
the	O	O
native	O	O
peptide	O	O
that	O	O
are	O	O
important	O	O
for	O	O
receptor	O	O
activation	O	O
.	O	O
Condensation	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoquinoline	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
with	O	O
ammonium	O	O
hydroxide	O	O
,	O	O
methylamine	O	O
,	O	O
ethylamine	O	O
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetylethylenediamine	I-IUPAC	I-IUPAC
gave	O	O
the	O	O
corresponding	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethylamino	I-IUPAC	I-IUPAC
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetylethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
which	O	O
were	O	O
then	O	O
converted	O	O
to	O	O
amides	O	O
and	O	O
subsequently	O	O
oxidized	O	O
to	O	O
aldehydes	O	O
followed	O	O
by	O	O
condensation	O	O
with	O	O
thiosemicarbazide	O	O
to	O	O
yield	O	O
thiosemicarbazones	O	O
8a	O	O
-	O	O
c	O	O
,	O	O
9a	O	O
-	O	O
c	O	O
,	O	O
and	O	O
16	O	O
.	O	O
Other	O	O
tetramethyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolinecarboxamide	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
by	O	O
acylating	O	O
the	O	O
aminoalkyl	B-IUPAC	O
compounds	B-MODIFIER	O
with	O	O
2,2,6,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetramethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinone	I-IUPAC	I-IUPAC
in	O	O
a	O	O
reaction	O	O
involving	O	O
Favorskii	O	O
rearrangement	O	O
.	O	O
Antiviral	O	O
evaluation	O	O
of	O	O
these	O	O
compounds	O	O
revealed	O	O
a	O	O
very	O	O
potent	O	O
antiherpetic	O	O
activity	O	O
associated	O	O
with	O	O
the	O	O
Northern	O	O
thymidine	O	O
analogue	O	O
2	O	O
,	O	O
which	O	O
was	O	O
more	O	O
powerful	O	O
than	O	O
the	O	O
reference	O	O
standard	O	O
acyclovir	O	O
against	O	O
both	O	O
HSV	O	O
-	O	O
1	O	O
and	O	O
HSV	O	O
-	O	O
2	O	O
.	O	O
However	O	O
,	O	O
the	O	O
hydrogen	O	O
-	O	O
bonding	O	O
network	O	O
for	O	O
each	O	O
class	O	O
of	O	O
ligand	O	O
is	O	O
somewhat	O	O
different	O	O
and	O	O
the	O	O
number	O	O
of	O	O
hydrogen	O	O
bonds	O	O
formed	O	O
between	O	O
PKC	O	O
and	O	O
these	O	O
ligands	O	O
has	O	O
no	O	O
correlation	O	O
with	O	O
their	O	O
binding	O	O
affinities	O	O
.	O	O
Administered	O	O
intraperitoneally	O	O
for	O	O
5	O	O
consecutive	O	O
days	O	O
,	O	O
1c	O	O
was	O	O
as	O	O
effective	O	O
as	O	O
FU	O	O
at	O	O
prolonging	O	O
the	O	O
life	O	O
span	O	O
of	O	O
mice	O	O
bearing	O	O
P	O	O
-	O	O
388	O	O
leukemia	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
two	O	O
series	O	O
of	O	O
novel	O	O
retinoids	O	O
(	O	B-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazinylcarboxamidobenzoates	I-IUPAC	I-IUPAC
and	O	O
beta	B-IUPAC	O
-	I-IUPAC	O
ionylideneacetamidobenzoates	I-IUPAC	O
)	O	O
have	O	O
been	O	O
investigated	O	O
by	O	O
evaluating	O	O
their	O	O
ability	O	O
to	O	O
induce	O	O
differentiation	O	O
in	O	O
both	O	O
human	O	O
promyelocytic	O	O
leukemia	O	O
(	O	O
HL60	O	O
)	O	O
cells	O	O
and	O	O
mouse	O	O
embryonal	O	O
carcinoma	O	O
(	O	O
P19	O	O
)	O	O
cells	O	O
.	O	O
The	O	O
analogues	O	O
5-9	O	O
(	O	O
IC50	O	O
values	O	O
&	O	O
gt	O	O
;	O	O
100	O	O
microM	O	O
,	O	O
Table	O	O
I	O	O
)	O	O
exist	O	O
largely	O	O
in	O	O
the	O	O
3,4	O	O
-	O	O
dipseudoaxial	O	O
conformation	O	O
(	O	O
as	O	O
evidenced	O	O
by	O	O
1H	O	O
NMR	O	O
spectra	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
3	O	B-IUPAC
-	O	I-IUPAC
cyano	O	I-IUPAC
derivative	O	B-MODIFIER
(	O	O
10	O	O
,	O	O
IC50	O	O
=	O	O
12.0	O	O
microM	O	O
)	O	O
has	O	O
a	O	O
relatively	O	O
high	O	O
population	O	O
of	O	O
the	O	O
3	O	O
-	O	O
pseudoequatorial	O	O
conformer	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
high	O	O
correlation	O	O
between	O	O
adenosine	O	O
binding	O	O
affinities	O	O
of	O	O
analogously	O	O
substituted	O	O
xanthines	O	O
and	O	O
pyrazolo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
and	O	O
the	O	O
close	O	O
superposition	O	O
of	O	O
the	O	O
heterocyclic	O	O
rings	O	O
and	O	O
substituents	O	O
that	O	O
is	O	O
apparent	O	O
from	O	O
molecular	O	O
models	O	O
of	O	O
these	O	O
two	O	O
series	O	O
,	O	O
it	O	O
is	O	O
hypothesized	O	O
they	O	O
fit	O	O
the	O	O
receptor	O	O
in	O	O
an	O	O
analogous	O	O
fashion	O	O
.	O	O
Moreover	O	O
,	O	O
compound	O	O
55	O	O
exhibited	O	O
a	O	O
fairly	O	O
high	O	O
ratio	O	O
of	O	O
antistereotypic	O	O
activity	O	O
to	O	O
cataleptogenicity	O	O
compared	O	O
with	O	O
haloperidol	O	O
and	O	O
metoclopramide	O	O
.	O	O
9,11	O	B-IUPAC
-	O	I-IUPAC
Secoestradiol	O	I-IUPAC
(	O	O
9	O	O
)	O	O
and	O	O
11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
secoestradiol	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
have	O	O
been	O	O
synthesized	O	O
starting	O	O
from	O	O
17	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyestradiol	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ether	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
and	O	O
found	O	O
to	O	O
possess	O	O
significant	O	O
antifertility	O	O
activity	O	O
in	O	O
rats	O	O
.	O	O
The	O	O
permanent	O	O
positive	O	O
charge	O	O
on	O	O
the	O	O
distal	O	O
nitrogen	O	O
atom	O	O
of	O	O
the	O	O
tricyclic	O	O
side	O	O
chain	O	O
contribution	O	O
to	O	O
binding	O	O
was	O	O
estimated	O	O
as	O	O
&	O	O
gt	O	O
;	O	O
/	O	O
=	O	O
5.6	O	O
kcal	O	O
.	O	O
The	O	O
aminolysis	O	O
protocol	O	O
used	O	O
here	O	O
has	O	O
distinct	O	O
advantages	O	O
over	O	O
either	O	O
reductive	O	O
cleavage	O	O
or	O	O
preformed	O	O
linker	O	O
methods	O	O
described	O	O
previously	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
octreotide	O	O
.	O	O
Alkylation	O	O
with	O	O
(	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
yielded	O	O
basic	O	O
cyclopropanes	O	O
.	O	O
Glucuronic	O	O
acid	O	O
linked	O	O
prodrugs	O	O
of	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanine	I-IUPAC	I-IUPAC
and	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyguanosine	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
.	O	O
Conversion	O	O
of	O	O
this	O	O
oxime	O	O
to	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phthalimido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiophenoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butanone	I-IUPAC	I-IUPAC
oxime	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
was	O	O
carried	O	O
out	O	O
by	O	O
its	O	O
reaction	O	O
with	O	O
potassium	O	O
phthalimide	O	O
using	O	O
crown	O	O
18	O	O
ether	O	O
as	O	O
a	O	O
catalyst	O	O
.	O	O
The	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deazaguanosine	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclic	I-IUPAC	I-IUPAC
phosphate	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
was	O	O
prepared	O	O
from	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyanomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphate	I-IUPAC	I-IUPAC
.	O	O
For	O	O
7b	O	O
,	O	O
the	O	O
initial	O	O
enzyme	O	O
velocity	O	O
is	O	O
not	O	O
a	O	O
saturable	O	O
function	O	O
of	O	O
the	O	O
inhibitor	O	O
concentration	O	O
and	O	O
the	O	O
initial	O	O
Ki	O	O
could	O	O
not	O	O
be	O	O
determined	O	O
(	O	O
Ki	O	O
&	O	O
gt	O	O
;	O	O
10	O	O
microM	O	O
)	O	O
.	O	O
Introduction	O	O
of	O	O
substituents	O	O
in	O	O
the	O	O
benzene	O	O
ring	O	O
of	O	O
the	O	O
spiro	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ring	O	B-MODIFIER
system	O	I-MODIFIER
of	O	O
Lu	O	O
28-179	O	O
mainly	O	O
affects	O	O
affinity	O	O
for	O	O
sigma	O	O
1	O	O
binding	O	O
sites	O	O
.	O	O
Larger	O	O
substituents	O	O
were	O	O
well	O	O
-	O	O
tolerated	O	O
by	O	O
the	O	O
receptor	O	O
,	O	O
but	O	O
the	O	O
smaller	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
bound	B-MODIFIER	O
with	O	O
lower	O	O
affinity	O	O
.	O	O
carinii	O	O
and	O	O
the	O	O
T	O	O
.	O	O
Among	O	O
the	O	O
various	O	O
compounds	O	O
screened	O	O
,	O	O
methyl	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
4c	O	O
)	O	O
has	O	O
shown	O	O
the	O	O
highest	O	O
adulticidal	O	O
activity	O	O
and	O	O
methyl	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
3a	O	O
)	O	O
has	O	O
shown	O	O
the	O	O
highest	O	O
microfilaricidal	O	O
action	O	O
against	O	O
A	O	O
.	O	O
Compounds	O	O
4	O	O
,	O	O
18	O	O
,	O	O
and	O	O
20	O	O
are	O	O
inhibitors	O	O
of	O	O
the	O	O
GABA	O	O
uptake	O	O
system	O	O
,	O	O
although	O	O
much	O	O
weaker	O	O
than	O	O
nipecotic	O	O
acid	O	O
and	O	O
(	B-IUPAC	B-IUPAC
3RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4SR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypiperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
21	O	O
)	O	O
.	O	O
The	O	O
thiadiazolopyrimidine	O	O
(	O	O
14	O	O
)	O	O
showed	O	O
activity	O	O
at	O	O
three	O	O
dose	O	O
levels	O	O
.	O	O
The	O	O
N	O	O
(	O	O
1	O	O
)	O	O
-	O	O
substituents	O	O
evaluated	O	O
ranged	O	O
in	O	O
size	O	O
from	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthalen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
naphthalen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
naphthalen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
anthracen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
anthracen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
anthracen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
pyren	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
.	O	O
These	O	O
target	O	O
compounds	O	O
with	O	O
stereochemical	O	O
diversity	O	O
were	O	O
synthesized	O	O
from	O	O
the	O	O
versatile	O	O
chiral	O	O
cyclopropane	O	O
units	O	O
(	B-PARTIUPAC	O
1S	I-PARTIUPAC	O
,	I-PARTIUPAC	O
2R	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyldiphenylsilyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formylcyclopropane	I-IUPAC	I-IUPAC
(	O	O
6	O	O
and	O	O
7	O	O
,	O	O
respectively	O	O
)	O	O
or	O	O
their	O	O
enantiomers	O	O
ent	O	O
-	O	O
6	O	O
and	O	O
ent	O	O
-	O	O
7	O	O
.	O	O
For	O	O
the	O	O
latter	O	O
compound	O	O
,	O	O
the	O	O
chloroethyl	O	B-IUPAC
group	O	B-MODIFIER
is	O	O
partially	O	O
(	O	O
at	O	O
pH	O	O
5.5	O	O
)	O	O
or	O	O
totally	O	O
(	O	O
at	O	O
pH	O	O
7.0	O	O
)	O	O
cyclized	O	O
into	O	O
aziridine	O	O
(	O	O
4b	O	O
-	O	O
2	O	O
)	O	O
,	O	O
which	O	O
is	O	O
then	O	O
progressively	O	O
hydrolyzed	O	O
into	O	O
an	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
(	O	O
4b	O	O
-	O	O
3	O	O
)	O	O
.	O	O
Several	O	O
Z	B-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
hydroxymethyl	I-IUPAC	O
)	I-IUPAC	O
methylenecyclopropanes	I-IUPAC	O
exhibited	O	O
in	O	O
vitro	O	O
antiviral	O	O
activity	O	O
in	O	O
micromolar	O	O
or	O	O
submicromolar	O	O
range	O	O
against	O	O
human	O	O
and	O	O
murine	O	O
cytomegalovirus	O	O
(	O	O
HCMV	O	O
and	O	O
MCMV	O	O
)	O	O
,	O	O
Epstein	O	O
-	O	O
Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
,	O	O
human	O	O
herpes	O	O
virus	O	O
6	O	O
(	O	O
HHV	O	O
-	O	O
6	O	O
)	O	O
,	O	O
varicella	O	O
zoster	O	O
virus	O	O
(	O	O
VZV	O	O
)	O	O
,	O	O
and	O	O
hepatitis	O	O
B	O	O
virus	O	O
(	O	O
HBV	O	O
)	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compounds	O	O
strongly	O	O
displaced	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
colchicine	O	O
from	O	O
its	O	O
binding	O	O
site	O	O
in	O	O
the	O	O
tubulin	O	O
,	O	O
yielding	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
3	O	O
-	O	O
to	O	O
4	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
colchicine	O	O
.	O	O
By	O	O
a	O	O
variety	O	O
of	O	O
synthetic	O	O
routes	O	O
,	O	O
we	O	O
have	O	O
synthesized	O	O
a	O	O
series	O	O
of	O	O
3,4,5	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
trisubstituted	I-MODIFIER	I-MODIFIER
4H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazoles	I-IUPAC	I-IUPAC
and	O	O
a	O	O
related	O	O
series	O	O
of	O	O
3H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazoles	I-IUPAC	I-IUPAC
and	O	O
evaluated	O	O
them	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
as	O	O
angiotensin	O	O
II	O	O
(	O	O
AII	O	O
)	O	O
antagonists	O	O
.	O	O
Various	O	O
structural	O	O
features	O	O
of	O	O
this	O	O
series	O	O
of	O	O
compounds	O	O
that	O	O
may	O	O
have	O	O
an	O	O
affinity	O	O
for	O	O
receptor	O	O
binding	O	O
sites	O	O
are	O	O
discussed	O	O
.	O	O
The	O	O
coplanarity	O	O
of	O	O
trans	O	O
isomers	O	O
and	O	O
the	O	O
flexibility	O	O
of	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexylamine	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
allow	O	O
them	O	O
easy	O	O
approach	O	O
to	O	O
the	O	O
target	O	O
DNA	O	O
.	O	O
The	O	O
16	O	O
new	O	O
analogues	O	O
are	O	O
(	O	O
1	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
D	O	O
-	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
]	O	O
AVP	O	O
,	O	O
(	O	O
2	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
D	O	O
-	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Val4	O	O
,	O	O
delta	O	O
3	O	O
-	O	O
Pro7	O	O
]	O	O
AVP	O	O
,	O	O
(	O	O
3	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
D	O	O
-	O	O
Tyr	O	O
-	O	O
(	O	O
Et	O	O
)	O	O
2	O	O
,	O	O
Val4	O	O
,	O	O
Lys8	O	O
]	O	O
VP	O	O
,	O	O
(	O	O
4	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
D	O	O
-	O	O
Tyr	O	O
(	O	O
Et	O	O
)	O	O
2	O	O
,	O	O
Val4	O	O
,	O	O
Cit8	O	O
]	O	O
VP	O	O
,	O	O
(	O	O
5	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
]	O	O
AVT	O	O
,	O	O
(	O	O
6	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Lys8	O	O
]	O	O
VT	O	O
,	O	O
(	O	O
7	O	O
)	O	O
dP	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
]	O	O
AVT	O	O
,	O	O
(	O	O
8	O	O
)	O	O
dP	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Val4	O	O
]	O	O
AVT	O	O
,	O	O
(	O	O
9	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
D	O	O
-	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Val4	O	O
]	O	O
AVT	O	O
,	O	O
(	O	O
10	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Val4	O	O
]	O	O
AVT	O	O
,	O	O
(	O	O
11	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Thr4	O	O
]	O	O
OVT	O	O
,	O	O
(	O	O
12	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Thr4	O	O
,	O	O
Ala	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
]	O	O
OVT	O	O
,	O	O
(	O	O
13	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Thr4	O	O
,	O	O
Leu	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
]	O	O
OVT	O	O
,	O	O
(	O	O
14	O	O
)	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Thr4	O	O
,	O	O
Arg	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
]	O	O
OVT	O	O
,	O	O
(	O	O
15	O	O
)	O	O
desGly	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Thr4	O	O
]	O	O
OVT	O	O
,	O	O
(	O	O
16	O	O
)	O	O
desGly9	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
,	O	O
Thr4	O	O
]	O	O
OVT	O	O
.	O	O
A	O	O
series	O	O
of	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
(	I-MODIFIER	I-MODIFIER
4	I-MODIFIER	I-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
homo	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzimidazoles	I-IUPAC	I-IUPAC
was	O	O
prepared	O	O
and	O	O
tested	O	O
for	O	O
H1	O	O
-	O	O
antihistaminic	O	O
activity	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O
All	O	O
analogues	O	O
were	O	O
tested	O	O
in	O	O
rats	O	O
for	O	O
agonistic	O	O
and	O	O
antagonistic	O	O
activities	O	O
in	O	O
oxytocic	O	O
(	O	O
in	O	O
vitro	O	O
,	O	O
without	O	O
and	O	O
with	O	O
Mg2+	O	O
,	O	O
and	O	O
in	O	O
vivo	O	O
)	O	O
assays	O	O
as	O	O
well	O	O
as	O	O
by	O	O
antidiuretic	O	O
and	O	O
vasopressor	O	O
assays	O	O
.	O	O
A	O	O
series	O	O
of	O	O
cyclic	O	O
analogues	O	O
was	O	O
synthesized	O	O
having	O	O
the	O	O
general	O	O
formula	O	O
cyclo	O	O
(	O	O
25-29	O	O
)	O	O
[	O	O
MeTyr1	O	O
,	O	O
-	O	O
Ala15	O	O
,	O	O
Xaa25	O	O
,	O	O
Nle27	O	O
,	O	O
Yaa29+	O	O
+	O	O
+	O	O
]	O	O
-	O	O
GHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
,	O	O
where	O	O
Xaa	O	O
and	O	O
Yaa	O	O
represent	O	O
the	O	O
bridgehead	O	O
residues	O	O
of	O	O
a	O	O
side	O	O
-	O	O
chain	O	O
cystine	O	O
or	O	O
[	O	O
i	O	O
-	O	O
(	O	O
i	O	O
+	O	O
4	O	O
)	O	O
]	O	O
lactam	O	O
ring	O	O
.	O	O
DNA	O	O
fragmentation	O	O
and	O	O
annexin	O	O
V	O	O
-	O	O
FITC	O	O
positive	O	O
cells	O	O
were	O	O
taken	O	O
as	O	O
parameters	O	O
of	O	O
apoptosis	O	O
whereas	O	O
NFkappa	O	O
-	O	O
B	O	O
activity	O	O
was	O	O
tested	O	O
by	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
reporter	O	O
vector	O	O
kappaB	O	O
-	O	O
luciferase	O	O
by	O	O
TNF	O	O
-	O	O
alpha	O	O
in	O	O
Hela	O	O
cells	O	O
.	O	O
According	O	O
to	O	O
the	O	O
data	O	O
presented	O	O
here	O	O
,	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
represents	O	O
a	O	O
typical	O	O
prodrug	O	O
:	O	O
a	O	O
compound	O	O
which	O	O
by	O	O
itself	O	O
shows	O	O
only	O	O
marginal	O	O
activity	O	O
but	O	O
over	O	O
time	O	O
it	O	O
is	O	O
chemically	O	O
hydrolyzed	O	O
to	O	O
the	O	O
fully	O	O
active	O	O
hormone	O	O
.	O	O
Substitution	O	O
of	O	O
halogens	O	O
in	O	O
the	O	O
phenyl	B-IUPAC	O
ring	B-MODIFIER	O
increased	O	O
potency	O	O
and	O	O
selectivity	O	O
for	O	O
the	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
-	O	O
adrenoceptor	O	O
,	O	O
and	O	O
this	O	O
was	O	O
dependent	O	O
upon	O	O
the	O	O
position	O	O
of	O	O
the	O	O
halogens	O	O
.	O	O
Substrate	O	O
and	O	O
inhibitor	O	O
properties	O	O
indicated	O	O
that	O	O
the	O	O
ATP	O	O
derivatives	O	O
are	O	O
potential	O	O
exco	O	O
-	O	O
ATP	O	O
-	O	O
site	O	O
-	O	O
directed	O	O
inactivators	O	O
of	O	O
hexokinases	O	O
,	O	O
adenylate	O	O
kinases	O	O
,	O	O
and	O	O
pyruvate	O	O
kinases	O	O
.	O	O
Glycosylated	O	O
antitumor	O	O
ether	O	O
lipids	O	O
(	O	O
GAELs	O	O
)	O	O
,	O	O
analogs	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycero	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphocholine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
,	O	O
ET	O	O
-	O	O
18	O	O
-	O	O
OCH3	O	O
,	O	O
edelfosine	O	O
)	O	O
,	O	O
were	O	O
synthesized	O	O
in	O	O
good	O	O
overall	O	O
yields	O	O
by	O	O
glycosylation	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycerol	I-IUPAC	I-IUPAC
and	O	O
tested	O	O
for	O	O
in	O	O
vitro	O	O
antineoplastic	O	O
activity	O	O
against	O	O
a	O	O
variety	O	O
of	O	O
murine	O	O
and	O	O
human	O	O
tumor	O	O
cell	O	O
lines	O	O
.	O	O
However	O	O
,	O	O
several	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboalkoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	O
substituted	I-IUPAC	B-MODIFIER
-	I-IUPAC	O
3alpha	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tropane	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
were	O	O
discovered	O	O
to	O	O
stimulate	O	O
locomotor	O	O
activity	O	O
and	O	O
substitute	O	O
in	O	O
subjects	O	O
trained	O	O
to	O	O
discriminate	O	O
cocaine	O	O
,	O	O
suggesting	O	O
a	O	O
role	O	O
of	O	O
the	O	O
2	O	O
-	O	O
position	O	O
substituent	O	O
in	O	O
mediating	O	O
these	O	O
cocaine	O	O
-	O	O
like	O	O
actions	O	O
.	O	O
Synthetic	O	O
routes	O	O
to	O	O
a	O	O
series	O	O
of	O	O
mono	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
difluorinated	B-IUPAC	O
2	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	O	I-IUPAC
substituted	B-MODIFIER	I-IUPAC
-	O	I-IUPAC
phenyl	B-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzothiazoles	I-IUPAC	I-IUPAC
have	O	O
been	O	O
devised	O	O
.	O	O
In	O	O
the	O	O
assay	O	O
for	O	O
D	O	O
-	O	O
2	O	O
receptor	O	O
mediated	O	O
inhibition	O	O
of	O	O
adenylate	O	O
cyclase	O	O
activity	O	O
,	O	O
all	O	O
the	O	O
tested	O	O
compounds	O	O
behaved	O	O
as	O	O
D	O	O
-	O	O
2	O	O
agonists	O	O
;	O	O
N	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
n	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
propyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
hydroxyphenyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
ethyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	O
18d	O	O
)	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
(	O	O
18b	O	O
)	O	O
were	O	O
more	O	O
effective	O	O
than	O	O
DA	O	O
or	O	O
2a	O	O
.	O	O
With	O	O
the	O	O
goal	O	O
of	O	O
developing	O	O
high	O	O
affinity	O	O
P2	O	O
-	O	O
purinoceptor	O	O
-	O	O
selective	O	O
agonist	O	O
,	O	O
we	O	O
have	O	O
synthesized	O	O
a	O	O
series	O	O
of	O	O
analogues	O	O
of	O	O
adenine	O	O
nucleotides	O	O
modified	O	O
on	O	O
the	O	O
purine	O	O
ring	O	O
as	O	O
chain	O	O
-	O	O
extended	O	O
2	O	B-IUPAC
-	O	I-IUPAC
thioethers	O	I-IUPAC
or	O	O
as	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
compounds	O	O
.	O	O
They	O	O
were	O	O
also	O	O
examined	O	O
for	O	O
their	O	O
inhibition	O	O
of	O	O
the	O	O
growth	O	O
of	O	O
the	O	O
L1210	O	O
cell	O	O
line	O	O
and	O	O
of	O	O
two	O	O
mutant	O	O
L1210	O	O
cell	O	O
lines	O	O
,	O	O
the	O	O
L1210	O	O
:	O	O
R7A	O	O
that	O	O
overproduces	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
and	O	O
the	O	O
L1210	O	O
:	O	O
1565	O	O
that	O	O
has	O	O
impaired	O	O
uptake	O	O
of	O	O
reduced	O	O
folates	O	O
.	O	O
Regression	O	O
analysis	O	O
suggested	O	O
a	O	O
requirement	O	O
for	O	O
optimally	O	O
sized	O	O
,	O	O
hydrophobic	O	O
5	O	O
-	O	O
and	O	O
7	O	O
-	O	O
substituents	O	O
,	O	O
with	O	O
bulk	O	O
tolerance	O	O
being	O	O
greater	O	O
at	O	O
the	O	O
5	O	O
-	O	O
position	O	O
.	O	O
Novel	O	O
3	O	O
-	O	O
substituted	O	O
analogues	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	I-IUPAC
3	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazacytidine	I-IUPAC	I-IUPAC
,	O	O
3	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	I-IUPAC
3	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazauridine	I-IUPAC	I-IUPAC
,	O	O
4	O	O
)	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
antitumor	O	O
and	O	O
antiviral	O	O
activity	O	O
.	O	O
The	O	O
conversion	O	O
of	O	O
the	O	O
monophenols	O	O
into	O	O
catecholic	O	O
metabolites	O	O
is	O	O
only	O	O
1-5%	O	O
,	O	O
and	O	O
the	O	O
further	O	O
conversion	O	O
of	O	O
these	O	O
catecholic	O	O
metabolites	O	O
into	O	O
methoxylated	O	O
analogues	O	O
is	O	O
very	O	O
rapid	O	O
.	O	O
The	O	O
major	O	O
factor	O	O
influencing	O	O
the	O	O
opioid	O	O
binding	O	O
of	O	O
the	O	O
similar	O	O
-	O	O
sized	O	O
heterocyclic	O	O
compounds	O	O
was	O	O
relative	O	O
lipophilicity	O	O
,	O	O
which	O	O
outweighed	O	O
electronic	O	O
character	O	O
.	O	O
For	O	O
the	O	O
preparation	O	O
of	O	O
the	O	O
iodine	O	O
-	O	O
125	O	O
-	O	O
labeled	O	O
benzamide	O	O
with	O	O
higher	O	O
specific	O	O
activity	O	O
,	O	O
this	O	O
method	O	O
was	O	O
unsuccessful	O	O
and	O	O
utilization	O	O
of	O	O
the	O	O
corresponding	O	O
tri	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyltin	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
was	O	O
required	O	O
.	O	O
Biological	O	O
activities	O	O
in	O	O
L1210	O	O
(	O	O
murine	O	O
leukemia	O	O
)	O	O
,	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
difluoromethylornithine	I-IUPAC	I-IUPAC
(	O	O
DFMO	O	O
)	O	O
-	O	O
treated	O	O
L1210	O	O
,	O	O
and	O	O
Chinese	O	O
hamster	O	O
ovary	O	O
(	O	O
CHO	O	O
)	O	O
and	O	O
its	O	O
polyamine	O	O
transport	O	O
-	O	O
deficient	O	O
mutant	O	O
(	O	O
CHO	O	O
-	O	O
MG	O	O
)	O	O
cell	O	O
lines	O	O
were	O	O
investigated	O	O
via	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
cytotoxicity	O	O
determinations	O	O
.	O	O
A	O	O
series	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylglyoxylylamides	I-IUPAC	I-IUPAC
(	O	O
4-8	O	O
)	O	O
was	O	O
synthesized	O	O
as	O	O
ligands	O	O
of	O	O
the	O	O
benzodiazepine	O	O
receptor	O	O
(	O	O
BzR	O	O
)	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
displace	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
flumazenil	O	O
from	O	O
bovine	O	O
brain	O	O
membranes	O	O
.	O	O
DCC	O	O
-	O	O
mediated	O	O
cyclization	O	O
of	O	O
17	O	O
,	O	O
followed	O	O
by	O	O
debenzylation	O	O
,	O	O
gave	O	O
pyrazofurin	O	O
3'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclic	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phosphate	I-IUPAC	I-IUPAC
(	O	O
21b	O	O
)	O	O
.	O	O
All	O	O
analogs	O	O
were	O	O
evaluated	O	O
in	O	O
the	O	O
in	O	O
vitro	O	O
5	O	O
-	O	O
HT1A	O	O
and	O	O
D2	O	O
binding	O	O
assays	O	O
and	O	O
selected	O	O
analogs	O	O
were	O	O
investigated	O	O
further	O	O
in	O	O
biochemical	O	O
and	O	O
behavioral	O	O
tests	O	O
.	O	O
The	O	O
strongly	O	O
increased	O	O
stereoselectivity	O	O
of	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
5	O	O
as	O	O
compared	O	O
to	O	O
that	O	O
of	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetralin	I-IUPAC	I-IUPAC
(	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
DPAT	O	O
;	O	O
1	O	O
)	O	O
is	O	O
rationalized	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
steric	O	O
factors	O	O
.	O	O
Reaction	O	O
of	O	O
bromide	O	O
1	O	O
with	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
chloromercuriopurine	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
saponification	O	O
yielded	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
compound	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyldodecanamide	I-IUPAC	I-IUPAC
(	O	O
35	O	O
,	O	O
TEI	O	O
-	O	O
6522	O	O
)	O	O
,	O	O
showed	O	O
significant	O	O
ACAT	O	O
inhibitory	O	O
activity	O	O
(	O	O
rabbit	O	O
small	O	O
intestine	O	O
IC50	O	O
=	O	O
13	O	O
nM	O	O
,	O	O
rabbit	O	O
liver	O	O
IC50	O	O
=	O	O
16	O	O
nM	O	O
)	O	O
,	O	O
foam	O	O
cell	O	O
formation	O	O
inhibitory	O	O
activity	O	O
(	O	O
rat	O	O
peritoneal	O	O
macrophage	O	O
IC50	O	O
=	O	O
160	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
extremely	O	O
potent	O	O
serum	O	O
cholesterol	O	O
-	O	O
lowering	O	O
activity	O	O
in	O	O
cholesterol	O	O
-	O	O
fed	O	O
rats	O	O
(	O	O
61%	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0.1	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
po	O	O
)	O	O
.	O	O
[	O	O
125I	O	O
]	O	O
2a	O	O
is	O	O
now	O	O
being	O	O
used	O	O
clinically	O	O
in	O	O
imaging	O	O
and	O	O
radiotherapy	O	O
of	O	O
catecholamine	O	O
tumors	O	O
,	O	O
such	O	O
as	O	O
pheochromocytoma	O	O
.	O	O
All	O	O
alpha	O	O
,	O	O
beta	O	O
-	O	O
unsaturated	O	O
carbonyl	O	O
compounds	O	O
obtained	O	O
exhibited	O	O
antiviral	O	O
activity	O	O
and	O	O
cytotoxicity	O	O
.	O	O
A	O	O
detailed	O	O
structure	O	O
-	O	O
activity	O	O
analysis	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
eight	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aralkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
nipecotamides	I-IUPAC	I-IUPAC
(	O	O
type	O	O
5	O	O
)	O	O
,	O	O
33	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nipecotamidoalkanes	I-IUPAC	I-IUPAC
and	O	O
aralkanes	B-IUPAC	O
(	O	O
type	O	O
6	O	O
)	O	O
,	O	O
and	O	O
7	O	B-IUPAC
N	B-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
nipecotoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperazines	I-IUPAC	I-IUPAC
(	O	O
type	O	O
7	O	O
)	O	O
as	O	O
inhibitors	O	O
of	O	O
human	O	O
platelet	O	O
aggregation	O	O
.	O	O
Several	O	O
compounds	O	O
display	O	O
high	O	O
affinity	O	O
to	O	O
serotonin	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
in	O	O
spite	O	O
of	O	O
major	O	O
differences	O	O
in	O	O
steric	O	O
bulk	O	O
and	O	O
electronic	O	O
properties	O	O
of	O	O
the	O	O
various	O	O
C11	O	O
-	O	O
substituents	O	O
.	O	O
Convenient	O	O
and	O	O
efficient	O	O
methods	O	O
were	O	O
developed	O	O
for	O	O
preparing	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorouracil	I-IUPAC	I-IUPAC
(	O	O
Thf	O	O
-	O	O
FU	O	O
,	O	O
3	O	O
)	O	O
[	O	O
trade	O	O
name	O	O
,	O	O
Futraful	O	O
(	O	O
Ftorafur	O	O
)	O	O
or	O	O
FT	O	O
-	O	O
207	O	O
]	O	O
,	O	O
which	O	O
is	O	O
used	O	O
clinically	O	O
as	O	O
an	O	O
antitumor	O	O
agent	O	O
,	O	O
and	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorouracil	I-IUPAC	I-IUPAC
(	O	O
Thf2	O	O
-	O	O
FU	O	O
,	O	O
4	O	O
)	O	O
.	O	O
The	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylindolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
imidazoline	I-IUPAC	I-IUPAC
6a	O	O
is	O	O
an	O	O
alpha	O	O
2	O	O
-	O	O
adrenergic	O	O
agonist	O	O
equal	O	O
in	O	O
potency	O	O
to	O	O
clonidine	O	O
in	O	O
vitro	O	O
,	O	O
while	O	O
the	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylindolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
imidazoline	I-IUPAC	I-IUPAC
6b	O	O
is	O	O
a	O	O
moderately	O	O
potent	O	O
alpha	O	O
2	O	O
-	O	O
adrenergic	O	O
antagonist	O	O
.	O	O
Thiazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
35	O	O
were	O	O
prepared	O	O
from	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bipyridin	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amines	I-IUPAC	I-IUPAC
30	O	O
and	O	O
32	O	O
via	O	O
a	O	O
four	O	O
-	O	O
step	O	O
sequence	O	O
.	O	O
Two	O	O
-	O	O
dimensional	O	O
nuclear	O	O
Overhauser	O	O
effect	O	O
(	O	O
NOESY	O	O
)	O	O
spectra	O	O
of	O	O
the	O	O
tomaymycin	O	O
-	O	O
d	O	O
(	O	O
ATGCAT	O	O
)	O	O
2	O	O
duplex	O	O
adduct	O	O
show	O	O
that	O	O
the	O	O
adducts	O	O
are	O	O
relatively	O	O
nondistortive	O	O
.	O	O
By	O	O
this	O	O
approach	O	O
compounds	O	O
such	O	O
as	O	O
(	B-IUPAC	B-IUPAC
3R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
adamantyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxymet	I-IUPAC	I-IUPAC
hyl	I-IUPAC	I-IUPAC
aminocarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3,4,5,6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
h	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazonine	I-IUPAC	I-IUPAC
(	O	O
32	O	O
)	O	O
were	O	O
prepared	O	O
.	O	O
carinii	O	O
or	O	O
T	O	O
.	O	O
The	O	O
oral	O	O
activity	O	O
of	O	O
the	O	O
prodrugs	O	O
was	O	O
modest	O	O
with	O	O
only	O	O
one	O	O
showing	O	O
2/4	O	O
cures	O	O
in	O	O
the	O	O
same	O	O
mouse	O	O
model	O	O
.	O	O
Another	O	O
derivative	O	O
of	O	O
this	O	O
compound	O	O
,	O	O
namely	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
(	O	O
5a	O	O
)	O	O
,	O	O
exhibited	O	O
the	O	O
highest	O	O
activity	O	O
against	O	O
L	O	O
.	O	O
Six	O	O
new	O	O
B	O	O
-	O	O
ring	O	O
analogues	O	O
of	O	O
the	O	O
nonpolyglutamatable	O	O
antifolate	O	O
Nalpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxypteroyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Ndelta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hemiphthaloy	I-IUPAC	I-IUPAC
l	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ornithine	I-IUPAC	I-IUPAC
(	O	O
PT523	O	O
,	O	O
3	O	O
)	O	O
were	O	O
synthesized	O	O
with	O	O
a	O	O
view	O	O
to	O	O
determining	O	O
the	O	O
effect	O	O
of	O	O
modifications	O	O
at	O	O
the	O	O
5	O	O
-	O	O
and	O	O
/	O	O
or	O	O
8	O	O
-	O	O
position	O	O
on	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
binding	O	O
and	O	O
tumor	O	O
cell	O	O
growth	O	O
inhibition	O	O
.	O	O
Methods	O	O
employed	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
tetramethoxydiphenylethane	B-IUPAC	O
intermediates	O	O
involved	O	O
(	O	O
1	O	O
)	O	O
arylmethyl	O	O
bromide	O	O
coupling	O	O
and	O	O
(	O	O
2	O	O
)	O	O
catalytic	O	O
hydrogenation	O	O
of	O	O
stilbene	O	O
intermediates	O	O
derived	O	O
via	O	O
Wittig	O	O
reaction	O	O
of	O	O
(	O	B-IUPAC
arylmethyl	O	I-IUPAC
)	O	I-IUPAC
phosphonium	O	I-IUPAC
salts	O	I-IUPAC
with	O	O
aryl	O	O
aldehydes	O	O
.	O	O
This	O	O
effect	O	O
on	O	O
TH	O	O
was	O	O
blocked	O	O
by	O	O
the	O	O
putative	O	O
sigma	O	O
-	O	O
receptor	O	O
antagonist	O	O
BMY	O	O
-	O	O
14802	O	O
,	O	O
suggesting	O	O
involvement	O	O
of	O	O
a	O	O
novel	O	O
neuromodulatory	O	O
sigma	O	O
-	O	O
like	O	O
receptor	O	O
.	O	O
High	O	O
specific	O	O
activity	O	O
[	O	O
(	O	O
123	O	O
)	O	O
I	O	O
]	O	O
ZIENT	O	O
and	O	O
[	O	O
(	O	O
123	O	O
)	O	O
I	O	O
]	O	O
EIENT	O	O
were	O	O
synthesized	O	O
in	O	O
45%	O	O
(	O	O
n	O	O
=	O	O
5	O	O
)	O	O
and	O	O
42%	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
radiochemical	O	O
yield	O	O
(	O	O
decay	O	O
-	O	O
corrected	O	O
to	O	O
end	O	O
of	O	O
bombardment	O	O
(	O	O
EOB	O	O
)	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
by	O	O
preparation	O	O
of	O	O
the	O	O
precursor	O	O
carbomethoxy	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethylstannylethenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
nortropane	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
and	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tributylstannylethenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
nortropane	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
followed	O	O
by	O	O
treatment	O	O
with	O	O
no	O	O
carrier	O	O
-	O	O
added	O	O
sodium	O	O
[	O	O
(	O	O
123	O	O
)	O	O
I	O	O
]	O	O
iodide	O	O
and	O	O
hydrogen	O	O
peroxide	O	O
in	O	O
ethanolic	O	O
HCl	O	O
.	O	O
The	O	O
characteristics	O	O
of	O	O
these	O	O
reactions	O	O
were	O	O
very	O	O
similar	O	O
to	O	O
those	O	O
previously	O	O
reported	O	O
for	O	O
the	O	O
oxidation	O	O
of	O	O
NOHA	O	O
by	O	O
NOS	O	O
:	O	O
(	O	O
i	O	O
)	O	O
the	O	O
strict	O	O
requirement	O	O
of	O	O
NOS	O	O
containing	O	O
(	B-IUPAC	B-IUPAC
6R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
biopterin	I-IUPAC	I-IUPAC
,	O	O
reduced	O	O
nicotinamide	O	O
adenine	O	O
dinucleotide	O	O
phosphate	O	O
,	O	O
and	O	O
O	O	O
(	O	O
2	O	O
)	O	O
for	O	O
the	O	O
oxidation	O	O
to	O	O
occur	O	O
,	O	O
(	O	O
ii	O	O
)	O	O
the	O	O
formation	O	O
of	O	O
NO	O	O
and	O	O
the	O	O
corresponding	O	O
urea	O	O
in	O	O
a	O	O
1	O	O
:	O	O
1	O	O
molar	O	O
ratio	O	O
,	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
a	O	O
strong	O	O
inhibitory	O	O
effect	O	O
of	O	O
the	O	O
classical	O	O
NOS	O	O
inhibitors	O	O
such	O	O
as	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
omega	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
and	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iso	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiourea	I-IUPAC	I-IUPAC
.	O	O
5	O	O
-	O	O
Chloro	O	O
-	O	O
dUMP	O	O
,	O	O
5	O	O
-	O	O
bromo	O	O
-	O	O
dUMP	O	O
,	O	O
and	O	O
5	O	O
-	O	O
iodo	O	O
-	O	O
dUMP	O	O
,	O	O
similar	O	O
to	O	O
dTMP	O	O
,	O	O
did	O	O
not	O	O
cause	O	O
a	O	O
time	O	O
-	O	O
dependent	O	O
inactivation	O	O
of	O	O
the	O	O
enzyme	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
affinity	O	O
relationships	O	O
of	O	O
these	O	O
2	O	O
-	O	O
substituted	O	O
aporphines	O	O
suggest	O	O
that	O	O
secondary	O	O
binding	O	O
sites	O	O
of	O	O
D2	O	O
receptors	O	O
interact	O	O
with	O	O
2	O	O
-	O	O
substituents	O	O
on	O	O
the	O	O
A	O	O
ring	O	O
of	O	O
aporphines	O	O
through	O	O
H	O	O
-	O	O
bonding	O	O
.	O	O
Several	O	O
of	O	O
the	O	O
novel	O	O
compounds	O	O
were	O	O
also	O	O
evaluated	O	O
for	O	O
their	O	O
ability	O	O
in	O	O
vivo	O	O
to	O	O
inhibit	O	O
clonic	O	O
seizures	O	O
induced	O	O
by	O	O
a	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
ip	O	O
)	O	O
dose	O	O
of	O	O
methyl	B-IUPAC	B-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
DMCM	O	O
)	O	O
.	O	O
The	O	O
epimers	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
4	O	O
proved	O	O
to	O	O
be	O	O
agonists	O	O
at	O	O
the	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptors	O	O
,	O	O
with	O	O
a	O	O
potency	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxytryptamine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
"	O	O
predicted	O	O
"	O	O
binding	O	O
model	O	O
for	O	O
phorbol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
13	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
is	O	O
virtually	O	O
identical	O	O
to	O	O
the	O	O
experimentally	O	O
determined	O	O
binding	O	O
model	O	O
for	O	O
this	O	O
ligand	O	O
.	O	O
Orotyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
leucyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
leucine	I-IUPAC	I-IUPAC
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
succinamoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
leucine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidinone	I-IUPAC	I-IUPAC
[	O	I-IUPAC
a	O	I-IUPAC
5	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
]	O	O
,	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoroorotyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
leucyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
leucine	I-IUPAC	I-IUPAC
all	O	O
inhibited	O	O
the	O	O
uptake	O	O
of	O	O
trimethionine	O	O
into	O	O
C	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperidines	I-IUPAC	I-IUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinols	I-IUPAC	I-IUPAC
and	O	O
the	O	O
corresponding	O	O
methyl	O	B-IUPAC
ethers	O	I-IUPAC
and	O	O
esters	O	O
display	O	O
weak	O	O
to	O	O
modest	O	O
antitetrabenazine	O	O
activity	O	O
.	O	O
Compounds	O	O
18	O	O
,	O	O
19b	O	O
,	O	O
20b	O	O
,	O	O
and	O	O
23b	O	O
also	O	O
exhibited	O	O
significant	O	O
inhibitory	O	O
effects	O	O
on	O	O
the	O	O
growth	O	O
of	O	O
L1210	O	O
and	O	O
P388	O	O
leukemias	O	O
and	O	O
Lewis	O	O
lung	O	O
carcinoma	O	O
cells	O	O
in	O	O
vitro	O	O
,	O	O
whereas	O	O
B16	O	O
melanoma	O	O
cells	O	O
were	O	O
less	O	O
sensitive	O	O
to	O	O
growth	O	O
inhibition	O	O
by	O	O
these	O	O
compounds	O	O
.	O	O
The	O	O
novel	O	O
agonists	O	O
described	O	O
inhibit	O	O
6	B-IUPAC	O
,	I-IUPAC	O
7	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
-	O	O
induced	B-MODIFIER	O
seizures	I-MODIFIER	O
,	O	O
and	O	O
in	O	O
mouse	O	O
locomotor	O	O
activity	O	O
higher	O	O
doses	O	O
are	O	O
required	O	O
to	O	O
reach	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
values	O	O
than	O	O
for	O	O
reference	O	O
A	O	O
(	O	O
1	O	O
)	O	O
agonists	O	O
.	O	O
This	O	O
compound	O	O
shows	O	O
low	O	O
cytotoxicity	O	O
in	O	O
human	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
and	O	O
also	O	O
has	O	O
favorable	O	O
properties	O	O
in	O	O
vivo	O	O
.	O	O
Several	O	O
diarylguanidines	O	O
structurally	O	O
related	O	O
to	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
o	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tolylguanidine	I-IUPAC	I-IUPAC
(	O	O
DTG	O	O
)	O	O
,	O	O
a	O	O
known	O	O
selective	O	O
sigma	O	O
receptor	O	O
ligand	O	O
,	O	O
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
in	O	O
in	O	O
vitro	O	O
radioligand	O	O
displacement	O	O
assays	O	O
,	O	O
with	O	O
rat	O	O
or	O	O
guinea	O	O
pig	O	O
brain	O	O
membrane	O	O
homogenates	O	O
,	O	O
using	O	O
the	O	O
NMDA	O	O
receptor	O	O
ion	O	O
channel	O	O
site	O	O
specific	O	O
radioligand	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cyclohepten	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imine	I-IUPAC	I-IUPAC
(	O	O
MK	O	O
-	O	O
801	O	O
,	O	O
3	O	O
)	O	O
,	O	O
and	O	O
the	O	O
sigma	O	O
receptor	O	O
-	O	O
specific	O	O
radioligand	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
o	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tolylguanidine	I-IUPAC	I-IUPAC
(	O	O
DTG	O	O
,	O	O
5	O	O
)	O	O
.	O	O
Reaction	O	O
conditions	O	O
for	O	O
the	O	O
Wittig	O	O
condensation	O	O
were	O	O
developed	O	O
using	O	O
the	O	O
tributylphosphorane	O	O
prepared	O	O
from	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pteridinediamine	I-IUPAC	I-IUPAC
(	O	O
7b	O	O
)	O	O
as	O	O
a	O	O
model	O	O
.	O	O
[	O	B-PARTIUPAC
1	B-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
N	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
methylisoleucine	I-IUPAC	I-PARTIUPAC
,	I-IUPAC	I-PARTIUPAC
8	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
threonine	I-IUPAC	I-PARTIUPAC
]	O	I-PARTIUPAC
-	O	I-PARTIUPAC
(	O	O
I	O	O
)	O	O
,	O	O
[	O	B-IUPAC
1	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylglycine	I-IUPAC	I-IUPAC
,	I-IUPAC	O
8	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
threonine	I-IUPAC	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
II	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
[	O	I-IUPAC
1	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
guanidineacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threonine	I-IUPAC	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
III	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
des	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threonine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
IV	O	I-IUPAC
)	O	I-IUPAC
,	O	O
and	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sarcosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylserine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
angiotensin	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
(	O	O
V	O	O
)	O	O
were	O	O
synthesized	O	O
by	O	O
Merrifield	O	O
's	O	O
solid	O	O
-	O	O
phase	O	O
procedure	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
(	O	O
a	O	O
)	O	O
substituents	O	O
in	O	O
position	O	O
1	O	O
on	O	O
the	O	O
antagonistic	O	O
activity	O	O
of	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sarcosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threonine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
angiotensin	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
,	O	O
and	O	O
(	O	O
b	O	O
)	O	O
a	O	O
change	O	O
in	O	O
size	O	O
and	O	O
branching	O	O
in	O	O
position	O	O
8	O	O
of	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sarcosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylthreonine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
angiotensin	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
.	O	O
The	O	O
sulfoxide	O	O
was	O	O
the	O	O
least	O	O
active	O	O
of	O	O
the	O	O
heteroretinoids	O	O
.	O	O
This	O	O
suggested	O	O
the	O	O
possibility	O	O
of	O	O
constraining	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
by	O	O
the	O	O
introduction	O	O
of	O	O
a	O	O
cyclo	O	O
(	O	O
1-3	O	O
)	O	O
scaffold	O	O
.	O	O
The	O	O
rest	O	O
of	O	O
the	O	O
ligands	O	O
had	O	O
poorer	O	O
affinities	O	O
with	O	O
Ki	O	O
values	O	O
between	O	O
10	O	O
and	O	O
28	O	O
microM	O	O
.	O	O
However	O	O
,	O	O
the	O	O
very	O	O
interesting	O	O
observation	O	O
was	O	O
made	O	O
that	O	O
,	O	O
when	O	O
inhibiting	O	O
COMT	O	O
by	O	O
means	O	O
of	O	O
tropolone	O	O
and	O	O
subsequently	O	O
treating	O	O
the	O	O
rats	O	O
with	O	O
high	O	O
doses	O	O
of	O	O
(	O	O
S	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
(	O	O
ip	O	O
)	O	O
,	O	O
postsynaptic	O	O
dopaminergic	O	O
activity	O	O
was	O	O
elicited	O	O
.	O	O
The	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
styryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
,	O	O
20	O	O
,	O	O
of	O	O
the	O	O
furanochromone	O	O
visnagin	O	O
was	O	O
30	O	O
-	O	O
fold	O	O
selective	O	O
for	O	O
human	O	O
A3	O	O
receptors	O	O
vs	O	O
either	O	O
rat	O	O
A1	O	O
or	O	O
A2A	O	O
receptors	O	O
.	O	O
Several	O	O
of	O	O
the	O	O
new	O	O
compounds	O	O
(	O	O
4-6	O	O
a	O	O
-	O	O
ej	O	O
-	O	O
l	O	O
)	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
the	O	O
growth	O	O
of	O	O
L1210	O	O
murine	O	O
leukemic	O	O
cells	O	O
.	O	O
Also	O	O
,	O	O
activity	O	O
was	O	O
diminished	O	O
or	O	O
destroyed	O	O
when	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropteridines	I-IUPAC	I-IUPAC
were	O	O
oxidized	O	O
to	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deazapteridines	I-IUPAC	I-IUPAC
or	O	O
reduced	O	O
to	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropteridines	I-IUPAC	I-IUPAC
.	O	O
These	O	O
four	O	O
molecules	O	O
were	O	O
evaluated	O	O
in	O	O
murine	O	O
leukemia	O	O
L1210	O	O
cells	O	O
for	O	O
their	O	O
impact	O	O
on	O	O
cell	O	O
proliferation	O	O
(	O	O
48	O	O
-	O	O
and	O	O
96	O	O
-	O	O
h	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
)	O	O
,	O	O
their	O	O
ability	O	O
to	O	O
compete	O	O
with	O	O
spermidine	O	O
for	O	O
the	O	O
polyamine	O	O
transport	O	O
apparatus	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
)	O	O
,	O	O
and	O	O
their	O	O
intracellular	O	O
accumulation	O	O
.	O	O
N6	O	O
-	O	O
Methyl	O	O
-	O	O
ATP	O	O
was	O	O
inactive	O	O
at	O	O
P2X	O	O
-	O	O
receptors	O	O
,	O	O
and	O	O
approximately	O	O
equipotent	O	O
to	O	O
ATP	O	O
at	O	O
taenia	O	O
coil	O	O
P2Y	O	O
-	O	O
receptors	O	O
.	O	O
Compound	O	O
13	O	O
(	O	O
methylhistaprodifen	O	O
;	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenylpropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethanamine	I-IUPAC	I-IUPAC
)	O	O
is	O	O
the	O	O
most	O	O
potent	O	O
histamine	O	O
H	O	O
(	O	O
1	O	O
)	O	O
-	O	O
receptor	O	O
agonist	O	O
reported	O	O
so	O	O
far	O	O
in	O	O
the	O	O
literature	O	O
and	O	O
may	O	O
become	O	O
a	O	O
valuable	O	O
tool	O	O
for	O	O
the	O	O
study	O	O
of	O	O
physiological	O	O
and	O	O
pathophysiological	O	O
H	O	O
(	O	O
1	O	O
)	O	O
-	O	O
receptor	O	O
-	O	O
mediated	O	O
effects	O	O
.	O	O
b	O	O
.	O	O
These	O	O
include	O	O
2'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
difluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
,	O	O
its	O	O
arabino	O	O
analogue	O	O
19	O	O
,	O	O
arabino	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcytosine	I-IUPAC	I-IUPAC
analogue	O	B-MODIFIER
21	O	O
,	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
didehydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorothymidine	I-IUPAC	I-IUPAC
(	O	O
25	O	O
)	O	O
,	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
(	O	O
29	O	O
)	O	O
,	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
(	O	O
31	O	O
)	O	O
,	O	O
and	O	O
2'	B-IUPAC	B-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
(	O	O
37	O	O
)	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
position	O	O
of	O	O
this	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
was	O	O
transferred	O	O
from	O	O
the	O	O
omega	O	O
-	O	O
phenyl	O	O
group	O	O
to	O	O
the	O	O
benzyl	O	B-IUPAC
or	O	O
phenyl	O	O
group	O	O
located	O	O
on	O	O
the	O	O
4	O	O
-	O	O
position	O	O
of	O	O
the	O	O
piperidine	O	O
ring	O	O
.	O	O
However	O	O
,	O	O
possible	O	O
conformations	O	O
of	O	O
the	O	O
first	O	O
residue	O	O
differ	O	O
and	O	O
depend	O	O
on	O	O
the	O	O
covalent	O	O
constraints	O	O
incorporated	O	O
into	O	O
the	O	O
side	O	O
chain	O	O
.	O	O
Competition	O	O
binding	O	O
experiments	O	O
with	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
NKA	O	O
were	O	O
performed	O	O
using	O	O
cloned	O	O
human	O	O
NK	O	O
-	O	O
2	O	O
receptors	O	O
expressed	O	O
in	O	O
CHO	O	O
cells	O	O
.	O	O
Racemic	O	O
6	O	O
and	O	O
11	O	O
did	O	O
not	O	O
substitute	O	O
in	O	O
(	O	B-IUPAC
S	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
amphetamine	O	I-IUPAC
-	O	O
trained	O	O
rats	O	O
.	O	O
The	O	O
high	O	O
specific	O	O
activity	O	O
one	O	O
-	O	O
step	O	O
radiolabeling	O	O
preparation	O	O
and	O	O
high	O	O
specificity	O	O
and	O	O
selectivity	O	O
of	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
R	O	O
)	O	O
-	O	O
FIPCT	O	O
and	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
S	O	O
)	O	O
-	O	O
FIPCT	O	O
for	O	O
DAT	O	O
indicate	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
R	O	O
)	O	O
-	O	O
FIPCT	O	O
and	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
S	O	O
)	O	O
-	O	O
FIPCT	O	O
are	O	O
potential	O	O
radioligands	O	O
for	O	O
mapping	O	O
brain	O	O
DAT	O	O
in	O	O
humans	O	O
using	O	O
PET	O	O
.	O	O
Their	O	O
structures	O	O
of	O	O
platinum	O	O
complexes	O	O
were	O	O
elucidated	O	O
from	O	O
circular	O	O
dichroism	O	O
and	O	O
13C	O	O
NMR	O	O
spectral	O	O
analyses	O	O
,	O	O
and	O	O
it	O	O
has	O	O
been	O	O
concluded	O	O
that	O	O
the	O	O
cyclohexane	O	O
ring	O	O
of	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanediamine	I-IUPAC	I-IUPAC
is	O	O
nearly	O	O
perpendicular	O	O
to	O	O
the	O	O
chelate	O	O
ring	O	O
,	O	O
while	O	O
both	O	O
rings	O	O
of	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanediamine	I-IUPAC	I-IUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexylamine	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
lie	O	O
in	O	O
a	O	O
common	O	O
plane	O	O
.	O	O
Additional	O	O
small	O	O
substituents	O	O
on	O	O
the	O	O
guanidine	O	O
nitrogen	O	O
atoms	O	O
bearing	O	O
the	O	O
aryl	O	O
rings	O	O
resulted	O	O
in	O	O
tri	O	O
-	O	O
and	O	O
tetrasubstituted	O	O
guanidine	O	O
derivatives	O	O
which	O	O
retained	O	O
affinity	O	O
for	O	O
NMDA	O	O
receptor	O	O
ion	O	O
channel	O	O
sites	O	O
but	O	O
exhibited	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
their	O	O
affinities	O	O
for	O	O
sigma	O	O
receptors	O	O
.	O	O
mu	O	O
binding	O	O
was	O	O
variable	O	O
,	O	O
with	O	O
KiS	O	O
in	O	O
excess	O	O
of	O	O
10,000	O	O
nM	O	O
for	O	O
most	O	O
analogs	O	O
,	O	O
and	O	O
all	O	O
of	O	O
the	O	O
analogs	O	O
bound	O	O
poorly	O	O
to	O	O
k	O	O
receptors	O	O
.	O	O
However	O	O
,	O	O
glycosylation	O	O
of	O	O
the	O	O
sodium	O	O
salt	O	O
of	O	O
4	O	O
with	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofurano	I-IUPAC	I-IUPAC
se	I-IUPAC	O
(	O	O
17	O	O
)	O	O
gave	O	O
exclusively	O	O
the	O	O
beta	O	O
-	O	O
anomers	O	O
(	O	O
19	O	O
and	O	O
21	O	O
)	O	O
in	O	O
good	O	O
yield	O	O
.	O	O
Crucially	O	O
,	O	O
these	O	O
studies	O	O
revealed	O	O
a	O	O
very	O	O
constrained	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
at	O	O
the	O	O
2	O	O
-	O	O
position	O	O
of	O	O
the	O	O
benzopyranone	O	O
and	O	O
pyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
pharmacophore	B-MODIFIER	I-IUPAC
,	O	O
with	O	O
only	O	O
a	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
morpholino	I-IUPAC	I-IUPAC
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylmorpholino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
being	O	O
tolerated	O	O
at	O	O
this	O	O
position	O	O
.	O	O
This	O	O
derivative	O	O
inhibited	O	O
FT	O	O
with	O	O
an	O	O
IC50	O	O
of	O	O
0.6	O	O
nM	O	O
and	O	O
inhibited	O	O
anchorage	O	O
-	O	O
independent	O	O
growth	O	O
of	O	O
stably	O	O
transformed	O	O
NIH	O	O
-	O	O
3T3	O	O
fibroblast	O	O
cells	O	O
by	O	O
50%	O	O
at	O	O
5	O	O
microM	O	O
.	O	O
The	O	O
dopaminergic	O	O
receptor	O	O
affinities	O	O
of	O	O
these	O	O
compounds	O	O
and	O	O
their	O	O
2	B-MODIFIER	O
-	I-MODIFIER	O
unsubstituted	I-MODIFIER	O
counterparts	I-MODIFIER	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
apomorphine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
(	O	O
-	O	O
)	O	O
-	O	O
APO	O	O
,	O	O
R	O	O
-	O	O
1	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
apomorphine	I-IUPAC	I-IUPAC
(	O	O
S	O	O
(	O	O
+	O	O
)	O	O
-	O	O
APO	O	O
,	O	O
S	O	O
-	O	O
1	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylnorapomorphine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
(	O	O
-	O	O
)	O	O
-	O	O
NPA	O	O
,	O	O
R	O	O
-	O	O
2	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
those	O	O
of	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroapomorphine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
-	O	O
Cl	O	O
-	O	O
APO	O	O
,	O	O
R	O	O
-	O	O
6	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromoapomorphine	I-IUPAC	I-IUPAC
(	O	O
R	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
-	O	O
Br	O	O
-	O	O
APO	O	O
,	O	O
R	O	O
-	O	O
6	O	O
)	O	O
,	O	O
were	O	O
determined	O	O
with	O	O
tissue	O	O
membrane	O	O
preparations	O	O
of	O	O
corpus	O	O
striatum	O	O
from	O	O
rat	O	O
brain	O	O
.	O	O
Synthesis	O	O
and	O	O
antitetrabenazine	O	O
activity	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperidines	I-IUPAC	I-IUPAC
,	O	O
prepared	O	O
as	O	O
simplified	O	O
and	O	O
possibly	O	O
more	O	O
readily	O	O
synthesized	O	O
analogues	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
,	O	O
are	O	O
reported	O	O
.	O	O
The	O	O
diastereoisomers	O	O
were	O	O
separated	O	O
by	O	O
column	O	O
chromatography	O	O
and	O	O
the	O	O
camphanates	O	O
and	O	O
the	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
removed	O	O
by	O	O
saponification	O	O
and	O	O
acid	O	O
hydrolysis	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
each	O	O
diastereoisomer	O	O
to	O	O
give	O	O
the	O	O
enantiomers	O	O
of	O	O
2,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
.	O	O
Compounds	O	O
in	O	O
series	O	O
3	O	O
tended	O	O
to	O	O
be	O	O
more	O	O
potent	O	O
,	O	O
10a	O	O
and	O	O
10c	O	O
having	O	O
scores	O	O
of	O	O
91	O	O
and	O	O
80%	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
transition	O	O
metal	O	O
complexes	O	O
[	B-IUPAC	O
eta	I-IUPAC	O
(	I-IUPAC	O
6	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
2beta	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyltropane	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tricarbonylchromium	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
[	B-IUPAC	O
eta	I-IUPAC	O
(	I-IUPAC	O
6	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
2beta	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyltropane	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
eta	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
pentamethylcyclopentadienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ruthenium	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
triflate	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
were	O	O
synthesized	O	O
from	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyltropane	I-IUPAC	I-IUPAC
(	O	O
2	O	O
,	O	O
WIN	O	O
35,065	O	O
)	O	O
to	O	O
further	O	O
elucidate	O	O
the	O	O
influence	O	O
of	O	O
substituents	O	O
on	O	O
the	O	O
3beta	O	O
-	O	O
aryl	O	O
on	O	O
the	O	O
affinity	O	O
of	O	O
the	O	O
ligand	O	O
for	O	O
cocaine	O	O
-	O	O
binding	O	O
sites	O	O
at	O	O
the	O	O
dopamine	O	O
transporter	O	O
.	O	O
We	O	O
conclude	O	O
that	O	O
two	O	O
of	O	O
the	O	O
novel	O	O
adenosine	O	O
derivatives	O	O
revealed	O	O
herein	O	O
,	O	O
12	B-PARTIUPAC	O
and	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
(	O	O
NNC	O	O
21-0147	O	O
,	O	O
13	O	O
)	O	O
,	O	O
representatives	O	O
of	O	O
a	O	O
new	O	O
series	O	O
of	O	O
P	O	O
(	O	O
1	O	O
)	O	O
ligands	O	O
,	O	O
reinforce	O	O
the	O	O
fact	O	O
that	O	O
novel	O	O
selective	O	O
adenosine	O	O
A	O	O
(	O	O
1	O	O
)	O	O
agonists	O	O
have	O	O
potential	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cerebral	O	O
ischemia	O	O
in	O	O
humans	O	O
.	O	O
Approximately	O	O
one	O	O
-	O	O
third	O	O
of	O	O
the	O	O
compounds	O	O
examined	O	O
exhibited	O	O
activity	O	O
against	O	O
both	O	O
maximal	O	O
electroshock	O	O
-	O	O
and	O	O
pentylenetetrazole	O	O
-	O	O
induced	O	O
seizures	O	O
in	O	O
mice	O	O
.	O	O
Further	O	O
21a	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
highly	O	O
selective	O	O
and	O	O
competitive	O	O
ACE	O	O
inhibitor	O	O
.	O	O
The	O	O
potency	O	O
and	O	O
selectivity	O	O
shown	O	O
by	O	O
some	O	O
of	O	O
these	O	O
ligands	O	O
for	O	O
the	O	O
NET	O	O
,	O	O
serotonine	O	O
transporter	O	O
(	O	O
SERT	O	O
)	O	O
,	O	O
or	O	O
NET	O	O
/	O	O
SERT	O	O
is	O	O
striking	O	O
,	O	O
particularly	O	O
in	O	O
view	O	O
of	O	O
the	O	O
displacement	O	O
of	O	O
the	O	O
aromatic	O	O
ring	O	O
in	O	O
this	O	O
series	O	O
from	O	O
its	O	O
usual	O	O
position	O	O
at	O	O
C	O	O
-	O	O
3	O	O
in	O	O
the	O	O
WIN	O	O
analogues	O	O
.	O	O
Internitrogen	O	O
spacings	O	O
had	O	O
a	O	O
large	O	O
effect	O	O
on	O	O
binding	O	O
affinity	O	O
and	O	O
subtype	O	O
selectivity	O	O
.	O	O
Here	O	O
we	O	O
report	O	O
the	O	O
syntheses	O	O
of	O	O
three	O	O
kinds	O	O
of	O	O
novel	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminothiophenes	I-IUPAC	I-IUPAC
and	O	O
assays	O	O
of	O	O
their	O	O
AE	O	O
activity	O	O
at	O	O
the	O	O
human	O	O
A	O	O
(	O	O
1	O	O
)	O	O
AR	O	O
(	O	O
hA	O	O
(	O	O
1	O	O
)	O	O
AR	O	O
)	O	O
,	O	O
namely	O	O
,	O	O
(	O	B-IUPAC
1	O	I-IUPAC
)	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenylthiophene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylates	I-IUPAC	I-IUPAC
,	O	O
3a	O	O
-	O	O
h	O	O
,	O	O
(	O	B-IUPAC
2	O	I-IUPAC
)	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenylthiophenes	I-IUPAC	I-IUPAC
,	O	O
7a	O	O
-	O	O
p	O	O
,	O	O
and	O	O
(	O	B-IUPAC
3	O	I-IUPAC
)	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylthiophenes	I-IUPAC	I-IUPAC
,	O	O
10a	O	O
-	O	O
h	O	O
.	O	O
X	O	O
-	O	O
ray	O	O
crystal	O	O
structures	O	O
were	O	O
determined	O	O
for	O	O
the	O	O
three	O	O
NHMe	O	O
derivatives	O	O
2	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5c	O	O
in	O	O
the	O	O
pyrido	B-PARTIUPAC	B-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
9,2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
d	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	I-PARTIUPAC	O
pyrido	I-PARTIUPAC	B-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
3,4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
d	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
pyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
,	O	O
respectively	O	O
.	O	O
Antagonists	O	O
at	O	O
the	O	O
1A	O	O
/	O	O
2B	O	O
subtype	O	O
of	O	O
the	O	O
NMDA	O	O
receptor	O	O
(	O	O
NR1A	O	O
/	O	O
2B	O	O
)	O	O
are	O	O
typically	O	O
small	O	O
molecules	O	O
that	O	O
consist	O	O
of	O	O
a	O	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
benzyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
or	O	O
a	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperidine	I-IUPAC	I-IUPAC
with	O	O
an	O	O
omega	B-IUPAC	O
-	I-IUPAC	O
phenylalkyl	I-IUPAC	O
substituent	B-MODIFIER	O
on	O	O
the	O	O
heterocyclic	O	O
nitrogen	O	O
.	O	O
These	O	O
results	O	O
strengthen	O	O
the	O	O
requirement	O	O
of	O	O
an	O	O
enamino	O	O
ester	O	O
for	O	O
binding	O	O
to	O	O
the	O	O
dihydropyridine	O	O
receptor	O	O
and	O	O
indicate	O	O
a	O	O
nonspecific	O	O
role	O	O
for	O	O
the	O	O
N3	O	O
-	O	O
substituent	O	O
.	O	O
mansoni	O	O
in	O	O
vivo	O	O
.	O	O
Condensation	O	O
of	O	O
14	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromodaunorubicin	I-IUPAC	I-IUPAC
with	O	O
thiols	O	O
in	O	O
methanol	O	O
,	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
potassium	O	O
carbonate	O	O
,	O	O
resulted	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
14	O	O
-	O	O
thia	O	O
analogues	O	O
of	O	O
the	O	O
antitumor	O	O
antibiotic	O	O
adriamycin	O	O
.	O	O
The	O	O
peripheral	O	O
benzodiazepine	O	O
receptor	O	O
(	O	O
PBR	O	O
)	O	O
is	O	O
widely	O	O
expressed	O	O
in	O	O
peripheral	O	O
tissues	O	O
,	O	O
blood	O	O
cells	O	O
,	O	O
and	O	O
in	O	O
glia	O	O
cells	O	O
in	O	O
the	O	O
brain	O	O
.	O	O
This	O	O
eutomer	O	O
was	O	O
tested	O	O
on	O	O
two	O	O
algesiometric	O	O
paradigms	O	O
and	O	O
,	O	O
because	O	O
of	O	O
the	O	O
interaction	O	O
with	O	O
alpha2	O	O
-	O	O
adrenoreceptors	O	O
,	O	O
showed	O	O
a	O	O
potent	O	O
and	O	O
long	O	O
-	O	O
lasting	O	O
antinociceptive	O	O
activity	O	O
,	O	O
since	O	O
it	O	O
was	O	O
abolished	O	O
by	O	O
the	O	O
selective	O	O
alpha2	O	O
-	O	O
antagonist	O	O
RX821002	O	O
.	O	O
Among	O	O
the	O	O
analogues	B-MODIFIER	O
,	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorobenzylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclopropane	I-IUPAC	I-IUPAC
(	O	O
11a	O	O
)	O	O
with	O	O
the	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopropane	I-IUPAC	I-IUPAC
structure	B-MODIFIER	B-MODIFIER
has	O	O
remarkable	O	O
antagonistic	O	O
activity	O	O
to	O	O
both	O	O
the	O	O
H3	O	O
(	O	O
Ki	O	O
=	O	O
8.4	O	O
nM	O	O
)	O	O
and	O	O
H4	O	O
(	O	O
Ki	O	O
=	O	O
7.6	O	O
nM	O	O
)	O	O
receptors	O	O
.	O	O
Compounds	O	O
with	O	O
substituents	O	O
(	O	O
F	O	O
,	O	O
CF3	O	O
)	O	O
in	O	O
the	O	O
4	O	O
-	O	O
or	O	O
7	O	O
-	O	O
position	O	O
of	O	O
the	O	O
isobenzofuran	O	O
display	O	O
high	O	O
affinity	O	O
for	O	O
sigma	O	O
2	O	O
binding	O	O
sites	O	O
(	O	O
IC50	O	O
(	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
0.5-2	O	O
nM	O	O
)	O	O
and	O	O
very	O	O
low	O	O
affinity	O	O
for	O	O
sigma	O	O
1	O	O
binding	O	O
sites	O	O
(	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
100	O	O
nM	O	O
)	O	O
.	O	O
Investigation	O	O
of	O	O
(	B-IUPAC	B-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
difluorocyclopentyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylacetamides	I-IUPAC	I-IUPAC
containing	O	O
a	O	O
phenyl	B-IUPAC	O
or	O	O
heterocyclic	B-IUPAC	O
ring	B-MODIFIER	O
as	O	O
the	O	O
piperidinyl	B-IUPAC	O
side	B-MODIFIER	O
chain	I-MODIFIER	O
in	O	O
place	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentenyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
of	O	O
15a	O	O
revealed	O	O
that	O	O
this	O	O
acid	O	O
moiety	O	O
was	O	O
a	O	O
versatile	O	O
template	O	O
for	O	O
improving	O	O
the	O	O
selectivity	O	O
for	O	O
M	O	O
(	O	O
3	O	O
)	O	O
over	O	O
M	O	O
(	O	O
2	O	O
)	O	O
receptors	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
corresponding	O	O
cyclopentylphenylacetic	O	O
acid	O	O
group	O	O
.	O	O
Surprisingly	O	O
,	O	O
3beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tropane	I-IUPAC	I-IUPAC
(	O	O
3p	O	O
)	O	O
and	O	O
3beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tropane	I-IUPAC	I-IUPAC
(	O	O
3r	O	O
)	O	O
did	O	O
not	O	O
produce	O	O
significant	O	O
increases	O	O
in	O	O
locomotor	O	O
activity	O	O
.	O	O
The	O	O
structural	O	O
assignment	O	O
of	O	O
7,8	O	O
,	O	O
and	O	O
20a	O	O
were	O	O
made	O	O
by	O	O
single	O	O
-	O	O
crystal	O	O
X	O	O
-	O	O
ray	O	O
analysis	O	O
,	O	O
and	O	O
along	O	O
with	O	O
pyrazofurin	O	O
,	O	O
their	O	O
intramolecular	O	O
hydrogen	O	O
bond	O	O
characteristics	O	O
have	O	O
been	O	O
studied	O	O
.	O	O
Ligands	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
3	O	O
,	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
7	O	O
,	O	O
and	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
8	O	O
were	O	O
synthesized	O	O
by	O	O
alkylation	O	O
of	O	O
phenol	O	O
precursor	O	O
9	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
iodopropane	I-IUPAC	I-IUPAC
(	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
10	O	O
)	O	O
,	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
iodoethane	I-IUPAC	I-IUPAC
(	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
11	O	O
)	O	O
,	O	O
and	O	O
[	B-IUPAC	O
(	I-IUPAC	O
11	I-IUPAC	O
)	I-IUPAC	O
C	I-IUPAC	O
]	I-IUPAC	O
iodomethane	I-IUPAC	O
(	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
12	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
Sulfur	O	O
-	O	O
bridged	O	O
pregnanes	O	O
6,19	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
epithioprogesterone	I-IUPAC	I-IUPAC
,	O	O
21	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,19	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epithioprogesterone	I-IUPAC	I-IUPAC
,	O	O
and	O	O
the	O	O
corresponding	O	O
sulfoxides	O	O
and	O	O
sulfones	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
as	O	O
blockers	O	O
of	O	O
the	O	O
immunosuppresive	O	O
activity	O	O
of	O	O
dexamethasone	O	O
in	O	O
rat	O	O
thymocytes	O	O
.	O	O
The	O	O
retention	O	O
of	O	O
glycine	O	O
/	O	O
NMDA	O	O
antagonist	O	O
activity	O	O
in	O	O
heterocyclic	O	O
ring	O	O
modified	O	O
analogues	O	O
,	O	O
such	O	O
as	O	O
the	O	O
oxanilide	O	O
69	O	O
and	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxybenzimidazole	I-IUPAC	I-IUPAC
70	O	O
,	O	O
suggests	O	O
that	O	O
the	O	O
4	B-IUPAC	O
-	I-IUPAC	O
oxo	I-IUPAC	O
tautomer	B-MODIFIER	O
of	O	O
1	O	O
and	O	O
its	O	O
derivatives	O	O
is	O	O
required	O	O
for	O	O
activity	O	O
.	O	O
Both	O	O
systems	O	O
compare	O	O
the	O	O
ability	O	O
of	O	O
chelators	O	O
to	O	O
remove	O	O
iron	O	O
from	O	O
the	O	O
liver	O	O
,	O	O
the	O	O
prime	O	O
target	O	O
organ	O	O
in	O	O
thalassemia	O	O
.	O	O
Molecular	O	O
mechanics	O	O
calculations	O	O
with	O	O
AMBER	O	O
show	O	O
that	O	O
the	O	O
two	O	O
species	O	O
with	O	O
the	O	O
thermodynamically	O	O
most	O	O
favorable	O	O
binding	O	O
energies	O	O
are	O	O
the	O	O
11R	O	O
,	O	O
11aS	O	O
and	O	O
11S	O	O
,	O	O
11aS	O	O
isomers	O	O
with	O	O
their	O	O
aromatic	O	O
rings	O	O
to	O	O
the	O	O
5'	O	O
and	O	O
3'	O	O
sides	O	O
of	O	O
the	O	O
covalently	O	O
bound	O	O
guanine	O	O
,	O	O
respectively	O	O
.	O	O
Of	O	O
the	O	O
compounds	O	O
tested	O	O
for	O	O
duration	O	O
of	O	O
action	O	O
(	O	O
1	O	O
,	O	O
3-6	O	O
,	O	O
8	O	O
)	O	O
,	O	O
we	O	O
found	O	O
6	O	O
and	O	O
8	O	O
to	O	O
be	O	O
slightly	O	O
longer	O	O
-	O	O
acting	O	O
than	O	O
astressin	O	O
or	O	O
[	O	O
DHis32	O	O
]	O	O
astressin	O	O
,	O	O
while	O	O
their	O	O
potencies	O	O
in	O	O
vitro	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
that	O	O
of	O	O
3	O	O
.	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5,6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
20a	O	O
)	O	O
,	O	O
or	O	O
the	O	O
corresponding	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
(	O	O
20b	O	O
)	O	O
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5,6	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
51	O	O
)	O	O
were	O	O
synthesized	O	O
by	O	O
regioselective	O	O
chromic	O	O
acid	O	O
oxidation	O	O
of	O	O
the	O	O
respective	O	O
bicyclic	O	O
tetrahydrobenzenes	O	O
19a	O	O
,	O	O
b	O	O
and	O	O
50	O	O
,	O	O
and	O	O
they	O	O
were	O	O
used	O	O
as	O	O
key	O	O
intermediates	O	O
for	O	O
the	O	O
syntheses	O	O
of	O	O
the	O	O
target	O	O
zwitterionic	O	O
3	B-IUPAC	O
-	I-IUPAC	O
isoxazolols	I-IUPAC	O
8-15	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
isothiazolols	I-IUPAC	I-IUPAC
16	O	O
and	O	O
17	O	O
,	O	O
respectively	O	O
.	O	O
All	O	O
compounds	O	O
investigated	O	O
exhibited	O	O
low	O	O
host	O	O
cell	O	O
toxicity	O	O
to	O	O
several	O	O
stationary	O	O
and	O	O
proliferating	O	O
host	O	O
cell	O	O
lines	O	O
as	O	O
well	O	O
as	O	O
mitogen	O	O
-	O	O
stimulated	O	O
proliferating	O	O
human	O	O
T	O	O
lymphocytes	O	O
.	O	O
Both	O	O
3	O	O
and	O	O
4	O	O
were	O	O
folylpolyglutamate	O	O
synthetase	O	O
(	O	O
FPGS	O	O
)	O	O
substrates	O	O
.	O	O
Differential	O	O
scanning	O	O
calorimetry	O	O
has	O	O
been	O	O
used	O	O
to	O	O
investigate	O	O
the	O	O
phase	O	O
behavior	O	O
of	O	O
the	O	O
lipid	O	O
bilayers	O	O
.	O	O
Despite	O	O
the	O	O
high	O	O
affinity	O	O
of	O	O
the	O	O
dextrorotatory	O	O
derivatives	O	O
for	O	O
the	O	O
mu	O	O
opioid	O	O
receptor	O	O
,	O	O
the	O	O
high	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
sigma	O	O
2	O	O
over	O	O
sigma	O	O
1	O	O
sites	O	O
will	O	O
surely	O	O
prove	O	O
beneficial	O	O
as	O	O
tools	O	O
for	O	O
the	O	O
delineation	O	O
of	O	O
the	O	O
function	O	O
and	O	O
physiological	O	O
role	O	O
of	O	O
sigma	O	O
2	O	O
receptors	O	O
.	O	O
The	O	O
[	O	O
2,3	O	O
-	O	O
dehydro	O	O
-	O	O
MeVal	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
AbA	O	O
was	O	O
the	O	O
most	O	O
potent	O	O
Pgp	O	O
inhibitory	O	O
aureobasidin	O	O
,	O	O
being	O	O
13	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
AbA	O	O
and	O	O
19	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
(	O	O
on	O	O
a	O	O
molar	O	O
basis	O	O
)	O	O
than	O	O
CsA	O	O
.	O	O
The	O	O
results	O	O
favor	O	O
the	O	O
hypothesis	O	O
that	O	O
weakly	O	O
polar	O	O
pi	O	O
-	O	O
pi	O	O
interactions	O	O
exist	O	O
between	O	O
the	O	O
aromatic	O	O
group	O	O
and	O	O
the	O	O
receptor	O	O
.	O	O
By	O	O
variation	O	O
of	O	O
the	O	O
substituents	O	O
in	O	O
the	O	O
benzene	O	O
part	O	O
of	O	O
the	O	O
indole	O	O
nucleus	O	O
in	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3-4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazolidinones	I-IUPAC	I-IUPAC
,	O	O
the	O	O
highest	O	O
5	O	O
-	O	O
HT2	O	O
receptor	O	O
affinity	O	O
and	O	O
selectivity	O	O
with	O	O
respect	O	O
to	O	O
dopamine	O	O
D2	O	O
receptors	O	O
and	O	O
alpha	O	O
1	O	O
adrenoceptors	O	O
were	O	O
obtained	O	O
by	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
substitution	B-MODIFIER	B-MODIFIER
.	O	O
Included	O	O
within	O	O
this	O	O
group	O	O
are	O	O
examples	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridylimidazopyridines	I-IUPAC	I-IUPAC
and	O	O
halo	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridylbenzimidazoles	I-IUPAC	I-IUPAC
.	O	O
The	O	O
hydrogen	O	O
-	O	O
bond	O	O
-	O	O
acceptor	O	O
properties	O	O
of	O	O
the	O	O
carbonyl	B-IUPAC	B-IUPAC
moiety	B-MODIFIER	B-MODIFIER
in	O	O
the	O	O
17beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
D	O	O
-	O	O
ring	O	O
of	O	O
the	O	O
anesthetic	O	O
steroids	O	O
(	B-PARTIUPAC	O
3alpha	I-PARTIUPAC	O
,	I-PARTIUPAC	O
5alpha	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
3alpha	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5beta	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypregan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
form	O	O
an	O	O
important	O	O
part	O	O
of	O	O
the	O	O
anesthetic	O	O
steroid	O	O
pharmacophore	O	O
.	O	O
A	O	O
number	O	O
of	O	O
agents	O	O
,	O	O
most	O	O
notably	O	O
14	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carbethoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
14	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiaadriamycin	I-IUPAC	I-IUPAC
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
14	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
14	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
selenaadriamycin	I-IUPAC	I-IUPAC
,	O	O
were	O	O
active	O	O
against	O	O
murine	O	O
L1210	O	O
leukemia	O	O
in	O	O
vivo	O	O
.	O	O
Various	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alkylamino	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alkoxy	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alkylthio	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfamoylbenzoic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
related	O	O
to	O	O
known	O	O
aminobenzoic	O	O
acid	O	O
diuretics	O	O
were	O	O
synthesized	O	O
and	O	O
screened	O	O
for	O	O
their	O	O
diuretic	O	O
properties	O	O
in	O	O
dogs	O	O
.	O	O
DNA	O	O
-	O	O
PK	O	O
inhibitory	O	O
activity	O	O
varied	O	O
widely	O	O
over	O	O
the	O	O
series	O	O
of	O	O
compounds	O	O
evaluated	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
ranged	O	O
from	O	O
0.19	O	O
to	O	O
&	O	O
gt	O	O
;	O	O
10	O	O
microM	O	O
)	O	O
,	O	O
with	O	O
excellent	O	O
activity	O	O
being	O	O
observed	O	O
for	O	O
the	O	O
7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzochromen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
and	O	O
pyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
templates	O	O
.	O	O
It	O	O
is	O	O
likely	O	O
that	O	O
the	O	O
lowered	O	O
affinity	O	O
in	O	O
this	O	O
bicyclo	B-IUPAC	O
[	I-IUPAC	O
3.1.0	I-IUPAC	O
]	I-IUPAC	O
hexane	I-IUPAC	O
series	B-MODIFIER	O
is	O	O
a	O	O
consequence	O	O
of	O	O
nonoptimal	O	O
geometry	O	O
(	O	O
pseudoequatorial	O	O
phenyl	O	O
or	O	O
pseudoboat	O	O
)	O	O
for	O	O
binding	O	O
as	O	O
opposed	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
steric	O	O
bulk	O	O
which	O	O
proved	O	O
deleterious	O	O
in	O	O
the	O	O
methylcyclohexyl	O	O
-	O	O
PCP	O	O
derivatives	O	O
.	O	O
For	O	O
the	O	O
syntheses	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trimethylsily	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorouracil	I-IUPAC	I-IUPAC
(	O	O
Me3Si	O	O
-	O	O
FU	O	O
,	O	O
1	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxytetrahydrofuran	I-IUPAC	I-IUPAC
(	O	O
Thf	O	O
-	O	O
OAc	O	O
,	O	O
2	O	O
)	O	O
were	O	O
condensed	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
Friedel	O	O
-	O	O
Crafts	O	O
catalysts	O	O
,	O	O
such	O	O
as	O	O
SnCl4	O	O
and	O	O
BF3	O	O
-	O	O
Et2O	O	O
in	O	O
dichloromethane	O	O
,	O	O
or	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
NaI	O	O
in	O	O
acetonitrile	O	O
to	O	O
give	O	O
Thf	O	O
-	O	O
Fu	O	O
or	O	O
Thf2	O	O
-	O	O
FU	O	O
depending	O	O
on	O	O
the	O	O
reaction	O	O
conditions	O	O
and	O	O
workup	O	O
procedure	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
thienylvinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazoles	I-IUPAC	I-IUPAC
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thienylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazoles	I-IUPAC	I-IUPAC
is	O	O
reported	O	O
.	O	O
The	O	O
calculations	O	O
revealed	O	O
an	O	O
REV	O	O
region	O	O
located	O	O
near	O	O
the	O	O
top	O	O
of	O	O
the	O	O
carbocyclic	O	O
ring	O	O
in	O	O
the	O	O
bottom	O	O
face	O	O
of	O	O
the	O	O
molecule	O	O
.	O	O
All	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
indanylamides	I-IUPAC	I-IUPAC
6	O	O
and	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indanylamides	I-IUPAC	I-IUPAC
8	O	O
were	O	O
devoid	O	O
of	O	O
any	O	O
appreciable	O	O
affinity	O	O
.	O	O
Glycosylation	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
with	O	O
4	O	O
and	O	O
subsequent	O	O
debenzoylation	O	O
gave	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
ribonucleoside	B-MODIFIER	I-IUPAC
(	O	O
13a	O	O
)	O	O
from	O	O
which	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
13b	O	O
)	O	O
was	O	O
obtained	O	O
by	O	O
amination	O	O
.	O	O
Our	O	O
SAR	O	O
studies	O	O
also	O	O
reveal	O	O
that	O	O
an	O	O
arenecarboxylic	O	O
acid	O	O
,	O	O
or	O	O
an	O	O
enoic	O	O
acid	O	O
in	O	O
which	O	O
the	O	O
carboxyl	B-IUPAC	O
group	B-MODIFIER	O
is	O	O
conjugated	O	O
with	O	O
the	O	O
central	O	O
ring	O	O
,	O	O
is	O	O
the	O	O
preferred	O	O
polar	O	O
group	O	O
.	O	O
Additionally	O	O
,	O	O
these	O	O
compounds	O	O
had	O	O
relatively	O	O
high	O	O
affinity	O	O
for	O	O
serotonin	O	O
5	O	O
-	O	O
HT1A	O	O
and	O	O
5	O	O
-	O	O
HT2A	O	O
,	O	O
dopamine	O	O
D2	O	O
,	O	O
and	O	O
adrenergic	O	O
alpha	O	O
1	O	O
receptors	O	O
.	O	O
A	O	O
series	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	B-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperidines	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridines	I-IUPAC	I-IUPAC
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperazines	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
.	O	O
The	O	O
beta	O	O
-	O	O
keto	O	O
derivative	O	O
was	O	O
converted	O	O
by	O	O
reaction	O	O
with	O	O
MeMgBr	O	O
,	O	O
and	O	O
after	O	O
reaction	O	O
with	O	O
thymine	O	O
and	O	O
subsequent	O	O
deprotection	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
and	O	O
its	O	O
beta	O	O
-	O	O
anomer	O	O
were	O	O
obtained	O	O
.	O	O
All	O	O
compounds	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
monoamine	O	O
reuptake	O	O
under	O	O
identical	O	O
conditions	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
these	O	O
series	O	O
of	O	O
flavonoids	O	O
provide	O	O
leads	O	O
for	O	O
the	O	O
development	O	O
of	O	O
novel	O	O
potent	O	O
and	O	O
subtype	O	O
selective	O	O
A3	O	O
antagonists	O	O
.	O	O
Yet	O	O
,	O	O
the	O	O
L	O	O
-	O	O
Phe	O	O
content	O	O
increased	O	O
,	O	O
indicating	O	O
that	O	O
a	O	O
covalent	O	O
bond	O	O
had	O	O
been	O	O
formed	O	O
between	O	O
the	O	O
inhibitor	O	O
and	O	O
the	O	O
enzyme	O	O
.	O	O
Each	O	O
of	O	O
the	O	O
isozymes	O	O
demonstrated	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
substrate	O	O
enantioselectivity	O	O
,	O	O
with	O	O
transferase	O	O
A	O	O
being	O	O
the	O	O
most	O	O
enantioselective	O	O
isozyme	O	O
.	O	O
The	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrazines	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
are	O	O
mitotic	O	O
inhibitors	O	O
with	O	O
significant	O	O
antitumor	O	O
activity	O	O
in	O	O
mice	O	O
.	O	O
Treatment	O	O
of	O	O
7,12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthraquinone	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
with	O	O
methylmagnesium	O	O
iodide	O	O
or	O	O
methyllithium	O	O
yields	O	O
mixtures	O	O
of	O	O
cis	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
7,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracenes	I-IUPAC	I-IUPAC
(	O	O
3a	O	O
,	O	O
b	O	O
)	O	O
,	O	O
in	O	O
which	O	O
the	O	O
ratio	O	O
of	O	O
cis	O	O
to	O	O
trans	O	O
lies	O	O
in	O	O
the	O	O
3	O	O
-	O	O
-	O	O
4	O	O
:	O	O
1	O	O
region	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
are	O	O
discussed	O	O
.	O	O
Through	O	O
this	O	O
series	O	O
of	O	O
analyses	O	O
,	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
hydrophilic	O	O
interaction	O	O
of	O	O
a	O	O
4beta	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
19	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diol	I-IUPAC	I-IUPAC
function	B-MODIFIER	O
with	O	O
the	O	O
active	O	O
site	O	O
of	O	O
aromatase	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
tight	O	O
binding	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ene	I-IUPAC	I-IUPAC
steroids	B-MODIFIER	B-MODIFIER
.	O	O
Replacement	O	O
of	O	O
the	O	O
polar	O	O
head	O	O
of	O	O
our	O	O
previous	O	O
series	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanomethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperazines	I-IUPAC	I-IUPAC
with	O	O
a	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
has	O	O
led	O	O
to	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
new	O	O
series	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
as	O	O
potent	O	O
,	O	O
orally	O	O
active	O	O
platelet	O	O
-	O	O
activating	O	O
factor	O	O
(	O	O
PAF	O	O
)	O	O
antagonists	O	O
.	O	O
The	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
and	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
gave	O	O
the	O	O
highest	O	O
percent	O	O
increases	O	O
in	O	O
life	O	O
span	O	O
for	O	O
mice	O	O
infected	O	O
with	O	O
L1210	O	O
leukemia	O	O
with	O	O
ILS	O	O
values	O	O
of	O	O
+	O	O
203	O	O
and	O	O
+	O	O
235%	O	O
,	O	O
respectively	O	O
.	O	O
A	O	O
similarly	O	O
reactive	O	O
intermediate	O	O
was	O	O
prepared	O	O
from	O	O
5	O	O
and	O	O
an	O	O
equimolar	O	O
amount	O	O
of	O	O
phosgene	O	O
in	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylacetamide	I-IUPAC	I-IUPAC
.	O	O
Tests	O	O
of	O	O
the	O	O
cytotoxicity	O	O
of	O	O
these	O	O
agents	O	O
to	O	O
oxygenated	O	O
and	O	O
chronically	O	O
hypoxic	O	O
EMT6	O	O
tumor	O	O
cells	O	O
in	O	O
culture	O	O
demonstrated	O	O
that	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
anthraquinone	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcarbamyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthraquinone	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluenesulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthraquinone	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
anthraquinone	I-IUPAC	I-IUPAC
were	O	O
significantly	O	O
more	O	O
toxic	O	O
to	O	O
hypoxic	O	O
cells	O	O
than	O	O
to	O	O
their	O	O
normally	O	O
aerated	O	O
counterparts	O	O
.	O	O
Last	O	O
,	O	O
neither	O	O
compound	O	O
displayed	O	O
dose	O	O
-	O	O
dependent	O	O
activation	O	O
of	O	O
alpha4beta2	O	O
nAChRs	O	O
.	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Lys4AVP	O	O
and	O	O
other	O	O
position	O	O
-	O	O
4	O	O
analogues	O	O
with	O	O
side	O	O
-	O	O
chain	O	O
functional	O	O
groups	O	O
may	O	O
be	O	O
useful	O	O
covalent	O	O
ligands	O	O
with	O	O
which	O	O
to	O	O
probe	O	O
the	O	O
structural	O	O
characteristics	O	O
of	O	O
AVP	O	O
renal	O	O
and	O	O
vascular	O	O
receptors	O	O
.	O	O
Med.	O	O
Chem.	O	O
1982	O	O
,	O	O
25	O	O
,	O	O
337-339	O	O
)	O	O
,	O	O
which	O	O
is	O	O
free	O	O
of	O	O
sedative	O	O
and	O	O
alcohol	O	O
interaction	O	O
potential	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
test	O	O
procedures	O	O
described	O	O
.	O	O
The	O	O
phenyl	B-IUPAC	O
group	B-MODIFIER	O
was	O	O
optionally	O	O
substituted	O	O
with	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
substituents	B-MODIFIER	B-MODIFIER
.	O	O
Two	O	O
chlorodiarylindenes	O	O
were	O	O
isolated	O	O
as	O	O
thermolysis	O	O
products	O	O
of	O	O
the	O	O
DTACs	O	O
,	O	O
and	O	O
one	O	O
was	O	O
converted	O	O
to	O	O
a	O	O
phenol	O	O
by	O	O
hydrogenolysis	O	O
.	O	O
The	O	O
sulfur	O	O
-	O	O
containing	O	O
ring	O	O
is	O	O
in	O	O
a	O	O
distorted	O	O
half	O	O
-	O	O
chair	O	O
in	O	O
1b	O	O
and	O	O
the	O	O
methyl	O	O
carbon	O	O
C	O	O
(	O	O
12	O	O
)	O	O
is	O	O
shown	O	O
to	O	O
be	O	O
trans	O	O
to	O	O
H	O	O
(	O	O
13	O	O
)	O	O
at	O	O
the	O	O
C	O	O
(	O	O
11	O	O
)	O	O
-	O	O
C	O	O
(	O	O
13	O	O
)	O	O
bond	O	O
.	O	O
We	O	O
measured	O	O
receptor	O	O
binding	O	O
affinity	O	O
using	O	O
recombinant	O	O
RAR	O	O
alpha	O	O
,	O	O
-	O	O
beta	O	O
,	O	O
and	O	O
-	O	O
gamma	O	O
proteins	O	O
and	O	O
assessed	O	O
cellular	O	O
differentiating	O	O
activity	O	O
in	O	O
F9	O	O
murine	O	O
teratocarcinoma	O	O
cells	O	O
(	O	O
F9	O	O
cells	O	O
)	O	O
.	O	O
The	O	O
potency	O	O
of	O	O
the	O	O
newly	O	O
synthesized	O	O
analogues	O	O
was	O	O
determined	O	O
in	O	O
the	O	O
stimulation	O	O
of	O	O
phospholipase	O	O
C	O	O
through	O	O
activation	O	O
of	O	O
turkey	O	O
erythrocyte	O	O
P2Y	O	O
(	O	O
1	O	O
)	O	O
or	O	O
human	O	O
P2Y	O	O
(	O	O
1	O	O
)	O	O
and	O	O
P2Y	O	O
(	O	O
2	O	O
)	O	O
receptors	O	O
stably	O	O
expressed	O	O
in	O	O
astrocytoma	O	O
cells	O	O
.	O	O
Our	O	O
goal	O	O
is	O	O
to	O	O
utilize	O	O
antagonists	O	O
of	O	O
the	O	O
serotonin	O	O
-	O	O
producing	O	O
enzymes	O	O
(	O	O
tryptophan	O	O
hydroxylase	O	O
and	O	O
AADC	O	O
)	O	O
as	O	O
the	O	O
basis	O	O
for	O	O
a	O	O
chemotherapeutic	O	O
approach	O	O
to	O	O
the	O	O
treatment	O	O
of	O	O
carcinoid	O	O
tumors	O	O
,	O	O
a	O	O
rare	O	O
tumor	O	O
type	O	O
characterized	O	O
by	O	O
the	O	O
overproduction	O	O
of	O	O
serotonin	O	O
.	O	O
In	O	O
the	O	O
systems	O	O
examined	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
exhibited	O	O
the	O	O
highest	O	O
affinity	O	O
for	O	O
kappa	O	O
receptors	O	O
,	O	O
with	O	O
a	O	O
Ki	O	O
of	O	O
44	O	O
+	O	O
/	O	O
-	O	O
8	O	O
nM	O	O
.	O	O
Routes	O	O
were	O	O
developed	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
congeners	O	O
of	O	O
3	O	O
by	O	O
cyclization	O	O
of	O	O
4	B-PARTIUPAC	B-MODIFIER
-	I-PARTIUPAC	I-MODIFIER
(	O	I-MODIFIER
substituted	B-MODIFIER	I-MODIFIER
amino	B-IUPAC	B-IUPAC
)	O	O
-	B-PARTIUPAC	B-PARTIUPAC
5,6	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
diaminopyridines	I-PARTIUPAC	I-PARTIUPAC
with	O	O
ethyl	O	O
orthoformate	O	O
.	O	O
Bromomethyl	O	O
intermediate	O	O
15	O	O
was	O	O
prepared	O	O
from	O	O
the	O	O
corresponding	O	O
hydroxymethyl	B-IUPAC	O
precursor	B-MODIFIER	O
14	O	O
by	O	O
treatment	O	O
with	O	O
48%	O	O
HBr	O	O
.	O	O
The	O	O
isomeric	B-MODIFIER	O
pivaloyloxymethyl	B-IUPAC	O
derivatives	B-MODIFIER	O
of	O	O
9	O	O
,	O	O
compounds	O	O
43	O	O
and	O	O
44	O	O
,	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
as	O	O
potential	O	O
prodrugs	O	O
in	O	O
the	O	O
isoniazide	O	O
animal	O	O
model	O	O
.	O	O
1-1	O	O
microM	O	O
range	O	O
against	O	O
13	O	O
cell	O	O
lines	O	O
(	O	O
52%	O	O
)	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Thio	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarbonitrile	I-IUPAC	I-IUPAC
was	O	O
obtained	O	O
from	O	O
butyl	B-IUPAC	B-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
sulfoxide	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
by	O	O
nitrosation	O	O
and	O	O
dehydration	O	O
of	O	O
the	O	O
oxime	O	O
.	O	O
The	O	O
displacement	O	O
of	O	O
[	B-PARTIUPAC	O
125I	I-PARTIUPAC	O
]	I-PARTIUPAC	O
(	I-PARTIUPAC	O
S	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
6b	O	O
and	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulpiride	I-IUPAC	I-IUPAC
from	O	O
their	O	O
respective	O	O
binding	O	O
sites	O	O
in	O	O
striatal	O	O
rat	O	O
brain	O	O
homogenates	O	O
using	O	O
various	O	O
neuroleptic	O	O
agents	O	O
showed	O	O
that	O	O
(	O	O
S	O	O
)	O	O
-	O	O
6b	O	O
has	O	O
the	O	O
same	O	O
binding	O	O
profile	O	O
but	O	O
more	O	O
potent	O	O
binding	O	O
for	O	O
dopamine	O	O
D	O	O
-	O	O
2	O	O
receptors	O	O
than	O	O
has	O	O
sulpiride	O	O
.	O	O
These	O	O
novel	O	O
compounds	O	O
are	O	O
derivatives	O	O
of	O	O
nipecotic	O	O
acid	O	O
,	O	O
guvacine	O	O
,	O	O
and	O	O
homo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
,	O	O
substituted	O	O
at	O	O
the	O	O
nitrogen	O	O
of	O	O
these	O	O
amino	O	O
acids	O	O
by	O	O
various	O	O
lipophilic	O	O
moieties	O	O
such	O	O
as	O	O
(	B-IUPAC	B-IUPAC
10,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
azepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkoxyalkyl	I-IUPAC	I-IUPAC
or	O	O
(	B-IUPAC	B-IUPAC
10,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cyclohepten	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkoxyalkyl	I-IUPAC	I-IUPAC
.	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Diacetoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroacronycine	I-IUPAC	I-IUPAC
(	O	O
17	O	O
)	O	O
was	O	O
the	O	O
most	O	O
active	O	O
,	O	O
all	O	O
the	O	O
treated	O	O
mice	O	O
being	O	O
tumor	O	O
-	O	O
free	O	O
on	O	O
day	O	O
23	O	O
.	O	O
An	O	O
axial	O	O
phenyl	B-MODIFIER	O
and	O	O
equatorial	B-MODIFIER	O
piperidine	B-IUPAC	O
ring	B-MODIFIER	O
with	O	O
the	O	O
nitrogen	O	O
lone	O	O
pair	O	O
of	O	O
electrons	O	O
antiperiplanar	O	O
to	O	O
the	O	O
phenyl	B-IUPAC	O
ring	B-MODIFIER	O
has	O	O
been	O	O
postulated	O	O
as	O	O
the	O	O
receptor	O	O
-	O	O
active	O	O
conformation	O	O
of	O	O
PCP	O	O
-	O	O
like	O	O
ligands	O	O
at	O	O
the	O	O
PCP	O	O
binding	O	O
site	O	O
.	O	O
The	O	O
corresponding	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
were	O	O
found	O	O
to	O	O
be	O	O
potent	O	O
D2	O	O
agonists	O	O
with	O	O
full	O	O
intrinsic	O	O
activity	O	O
.	O	O
A	O	O
series	O	O
of	O	O
compounds	O	O
related	O	O
to	O	O
ethyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxybenzoate	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
potential	O	O
hypolipidemic	O	O
activity	O	O
in	O	O
rats	O	O
.	O	O
Ex	O	O
vivo	O	O
autoradiography	O	O
showed	O	O
that	O	O
the	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
ligands	O	O
preferably	O	O
distributed	O	O
in	O	O
the	O	O
olfactory	O	O
bulb	O	O
and	O	O
cerebellum	O	O
,	O	O
two	O	O
regions	O	O
with	O	O
richer	O	O
PBR	O	O
density	O	O
in	O	O
the	O	O
rat	O	O
brain	O	O
.	O	O

